Kasan Insight :: 과학, 기술 그리고 법 - 제약/화학/바이오 분야의 실용적 법률정보와 해결방안

KASAN_국제계약, 영문계약 상표사용허락 라이선스 계약서 샘플 – MIT 대학 로고 상표라이선스 계약서.pdf

Tags : 계약조항샘플, 국제계약, 기술이전, 독점계약, 라이선스, 바이오신약, 상표라이센스, 상표사용허락, 영문계약, 전용사용권

작성일시 : 2019.06.14 09:11
Trackback 0 : Comment 0

국제계약, 영문계약 상표사용허락 라이선스 계약서 샘플 – MIT 대학 로고 상표라이선스 계약서

T R A D E M A R K L I C E N S E A G R E E M E N T

This License Agreement ("Agreement") is effective as of the date above the signatures of the parties below("EFFECTIVE DATE") by and between the MIT, a corporation duly organized and existing under the laws of the Commonwealth of Massachusetts, having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, U.S.A. ("MIT"), and ____, a corporation duly organized under the laws of __, having its principal office at ___("LICENSEE").

1. BACKGROUND

1.1 MIT owns rights in certain marks now and previously used by MIT and has acquired public recognition and goodwill through the use of such marks.

1.2 LICENSEE recognizes the goodwill appurtenant to use of said marks and desires to obtain a license to use certain of such marks. MIT is willing to grant such a license under the terms and conditions of this Agreement.

2. DEFINITIONS

2.1 LICENSED MARKS shall mean those marks listed in Appendix A.

2.2 LICENSED PRODUCTS shall mean the products in the categories specified in Appendix B that bear a LICENSED MARK.

2.3 TERRITORY shall mean U.S.A. and Canada only.

2.4 NET SALES PRICE shall mean LICENSEE's billing price to customers or distributors, less (1)discounts given that are customary in the trade, (2) returns, (3) transportation charges on returns if paid by LICENSEE, (4) taxes, and (5) prepaid transportation charges on LICENSED PRODUCTS SOLD by LICENSEE.

2.5 SOLD (or SALE) shall mean the first to occur of a LICENSED PRODUCT being shipped, distributed, paid for, billed or invoiced.

2.6 TERM shall mean the effective period of this Agreement, which shall commence on the EFFECTIVE DATE and which shall terminate on the fifth anniversary of the EFFECTIVE DATE.

3. LICENSE GRANT

3.1 Subject to the terms and conditions of this Agreement, MIT grants to LICENSEE the nonexclusive right to use, sell and have sold LICENSED PRODUCTS in the TERRITORY during the TERM hereof. In addition, MIT grants to LICENSEE, during the TERM, the nonexclusive right to manufacture and have manufactured the LICENSED PRODUCTS within and outside the United States, provided that LICENSEE and any manufacturers with whom LICENSEE subcontracts comply with MIT's Code of Conduct, further described in Paragraph 3.3.

3.2 LICENSEE shall not sublicense any of the rights granted hereunder.

3.3 LICENSEE acknowledges that MIT desires that LICENSEE not engage in practices that adversely affect the dignity and welfare of the workers who manufacture or produce the LICENSED PRODUCTS. MIT has adopted a Code of Conduct that regulates the conditions of manufacture of LICENSED PRODUCTS. MIT has attached the current version of the Code of Conduct as Appendix C hereto, thereby becoming a part of LICENSEE's obligations under this Agreement. MIT reserves the right to amend its Code of Conduct from time to time and attach it to this Agreement. Any LICENSEE who is unable or unwilling to comply with the amended Code of Conduct, as it exists from time to time, shall be allowed to terminate this Agreement within ninety (90) days after receipt of the revised Code of Conduct from MIT.

4. PAYMENTS

4.1 Delivered with LICENSEE's signed Agreement, LICENSEE shall pay to MIT a non- refundable License Issue Fee of One Hundred Dollars ($100.00). This fee is not creditable to future royalties due hereunder.

4.2 LICENSEE shall pay to MIT an annual non-refundable, non-creditable License Maintenance Fee of One Hundred Dollars ($100.00), due on each anniversary of the EFFECTIVE DATE during the TERM.

4.3 In addition to the License Issue Fee and annual License Maintenance Fee, LICENSEE shall pay to MIT a continuing royalty of seven and one half percent (7.5%) of the NET SALES PRICE of all LICENSED PRODUCTS SOLD by LICENSEE. If LICENSEE has SOLD any LICENSED PRODUCTS to any party affiliated with LICENSEE, or in any way directly or indirectly related to or under common control with LICENSEE, at a price less than the regular price charged to other parties, the royalties payable hereunder shall be computed on the basis of the regular price charged to nonaffiliated parties. There shall be no deduction from the royalties owed for uncollectible accounts or for advertising or other expenses of any kind which may be incurred or paid by LICENSEE, except those specifically enumerated in Paragraph 2.4 above.

4.4 Royalty payments shall be due within thirty (30) days of the end of each calendar quarter and shall be accompanied by the royalty reports described in Paragraph 5.2 below. Royalty payments shall be payable in United States dollars to "Massachusetts Institute of Technology" at the location in Paragraph 12.1 below, or at such other place as MIT may reasonably designate consistent with the laws and regulations controlling in any foreign country. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the conversion rate existing in the United States, as reported in the Wall Street Journal, on the last working day of the calendar quarter of the reporting period to which such royalty payments relate.

4.5 The royalty payments set forth in this Agreement shall, if overdue, bear interest, to the extent permitted by law, at five (5) percentage points above the Prime Rate of interest as reported in the Wall Street Journal on the date payment is due. The payment of such interest shall not foreclose MIT from exercising any other rights it may have as a consequence of the lateness of any payment.

5. REPORTS AND RECORDS

5.1 LICENSEE shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of showing the amounts payable to MIT hereunder. Such books of account shall be kept at LICENSEE's principal place of business or the principal place of business of the appropriate Division of LICENSEE to which this Agreement relates.

Such books and the supporting data shall be open at all reasonable times for five (5) years following the end of the calendar year to which they pertain to the inspection of MIT or its agents for the purpose of verifying LICENSEE's royalty statement or compliance in other respects with this Agreement.

In the event that any audit performed under this paragraph reveals an underpayment in excess of five percent (5%), LICENSEE shall bear the full cost of such audit and shall remit any amounts due to MIT within thirty (30) days of receiving notice thereof from MIT.

5.2 Within thirty (30) days after each calendar quarter during the TERM, LICENSEE shall deliver to MIT true and accurate reports giving such particulars of the business conducted by LICENSEE during the preceding calendar quarter as shall be pertinent to a royalty accounting hereunder. These reports shall include at least the following: (a) A description, broken out under each individual trademark, of all LICENSED PRODUCTS manufactured and SOLD. (b) Total billings, broken out under each individual trademark, for LICENSED PRODUCTS SOLD. (c) Deductions applicable as provided in Paragraph 2.4. (d) Total royalties due. (e) Names and addresses of LICENSEE's retail sellers of LICENSED PRODUCTS.

5.3 With each such report submitted, LICENSEE shall pay to MIT the royalties due and payable under this Agreement. If no royalties shall be due, LICENSEE shall so report.

6. TERMINATION

6.1 MIT may terminate this Agreement immediately upon written notice to LICENSEE upon the following: (a) If LICENSEE shall cease to carry on its business; (b) In the event LICENSEE fails to submit timely reports or payments due hereunder, and fails to submit such reports or make such payments within thirty (30) days after receiving written notice of such failure; (c) If, after expiration of the ninety (90) day grace period set forth in Paragraph 3.3, LICENSEE fails to comply with MIT's adopted Code of Conduct or any changes thereto; or (d) In the event LICENSEE commits a material breach of its obligations under this Agreement, except for breach as described in (a) through (c) of this Paragraph, and fails to cure that breach within ninety (90) days after receiving written notice of such breach.

6.2 LICENSEE may terminate this Agreement for any reason, (i) upon at least six (6) months prior written notice to MIT, such notice to state the date at least six (6) months in the future upon which termination is to be effective, and (ii) upon payment of all amounts due to MIT through such termination effective date.

6.3 Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination. The following provisions shall survive the expiration or termination of this Agreement: Articles 2, 7, 10 and 13, and Paragraphs 5.1, 5.2 (obligation to provide final report and payment), 6.3, and 6.4.

6.4 Upon expiration or termination of this Agreement, all rights granted to LICENSEE hereunder shall cease, and LICENSEE shall refrain from further use of the LICENSED MARKS in any manner. LICENSEE acknowledges that failure to comply with this provision shall result in immediate and irreparable harm affording injunctive and any and all other appropriate relief to MIT.

6.5 Upon expiration or termination of this Agreement, LICENSEE shall not operate its business in any manner which would falsely suggest to the public that this Agreement is still in force or that any relationship exists between LICENSEE and M.I.T.

7. GOODWILL IN LICENSED MARKS

7.1 LICENSEE agrees that the essence of this Agreement is founded on the goodwill associated with the LICENSED MARKS and value of that goodwill in the minds of the consuming public. LICENSEE agrees that it is critical that such goodwill be protected and enhanced and, toward this end, LICENSEE shall not during the TERM or thereafter:

(a) attack the title or any rights of MIT in or to the LICENSED MARKS; (b) apply to register or maintain any application or registration of the LICENSED MARKS or any other mark confusingly similar thereto in any jurisdiction, domestic or foreign; (c) use any colorable imitation of any of the LICENSED MARKS, or any variant form (including variant design forms, logos, colors, or typestyles) of the LICENSED MARKS not specifically approved by MIT; (d) misuse the LICENSED MARKS; (e) take any action that would bring the LICENSED MARKS into public disrepute; (f) use the LICENSED MARKS, or any mark or name confusingly similar thereto, in its corporate or trade name; or (g) take any action that would tend to destroy or diminish the goodwill in the LICENSED MARKS.

7.2 All use by LICENSEE of the LICENSED MARKS shall inure to the benefit of MIT.

7.3 LICENSEE agrees to cooperate fully with MIT in securing and maintaining the goodwill of MIT in the LICENSED MARKS.

7.4 Upon becoming aware of any third party infringement of the LICENSED MARKS, LICENSEE shall promptly advise MIT of such infringement, including the name and location of such infringer.

8. QUALITY CONTROL; PACKAGING AND ADVERTISING APPROVAL

8.1 All LICENSED PRODUCTS shall be of a quality acceptable to MIT LICENSEE acknowledges that if LICENSED PRODUCTS manufactured and SOLD by it are of inferior quality in design, material or workmanship, the substantial goodwill that MIT possesses in the LICENSED MARKS would be impaired.

Accordingly, LICENSEE agrees that all LICENSED PRODUCTS shall be of high quality. To this end, LICENSEE shall furnish to MIT, free of cost, for its approval, a sample of each LICENSED PRODUCT, together with any carton or container, packing or wrapping material. MIT shall have fourteen (14) days from receipt of each LICENSED PRODUCT in which to approve the sample.

In absence of approval, the sample shall be deemed as rejected as an example of the quality for the LICENSED PRODUCT. The LICENSED MARKS may be applied by LICENSEE only to such LICENSED PRODUCTS as are manufactured in accordance with the corresponding samples accepted hereunder and that have substantially the same relative quality position in the market place as do the samples thereof; provided, however, LICENSEE may furnish to MIT a further sample of any LICENSED PRODUCT of which it desires to change the quality, style and/or appearance and MIT shall have fourteen (14) days from receipt thereof in which to approve in writing said further sample. Failure to approve shall be deemed rejection thereof as an example of quality for that LICENSED PRODUCT.

MIT shall have the right through its employee(s) or designated representative(s) during normal business hours to inspect the facilities and product inventory of LICENSEE to assure itself that such acceptable level of quality is being maintained at all times. 8.2 Prior to any sale or commercial use, an example of each graphic design incorporating the LICENSED MARKS shall be provided to MIT for its approval and MIT shall have fourteen (14) days from receipt thereof in which to approve in writing said graphic design. Failure to approve shall be deemed as rejection thereof for that graphic design.

8.3 All packaging and advertising bearing the LICENSED MARKS shall be subject to the approval of MIT LICENSEE shall furnish to MIT one (1) copy of any packaging and advertisement of LICENSED PRODUCT used by LICENSEE. MIT shall have fourteen (14) days from receipt thereof in which to approve in writing the packaging or advertising materials. In the absence of approval, the packaging and advertising materials shall be deemed as rejected. LICENSEE shall furnish to MIT a further sample of packaging and advertising if it desires to change the packaging or advertising. MIT shall have fourteen (14) days to approve such changed packaging and advertising.

8.4 MIT's failure to approve under Paragraphs 8.1, 8.2 and 8.3 above shall be deemed rejection, unless MIT shall have requested within any such fourteen (14) day period an additional period of time (no greater than two (2) additional weeks) for further consideration of the material in question, in which case the initial period for MIT consideration and approval shall be extended by such additional period of time. MIT reserves the right to revise its quality and design criteria at any time and to rereview, pursuant to this Article 8, LICENSEE's merchandise and graphic designs for compliance with such criteria. 8.5 Graphic designs of LICENSED MARKS must conform to the MIT Merchandise Style Guide attached hereto as Appendix D, which can be changed at MIT’s reasonable discretion upon ninety (90) days notice.

9. MARKING

LICENSEE agrees that it shall mark the LICENSED PRODUCTS to indicate the rights of MIT in the LICENSED MARKS, including registration status of the LICENSED MARKS and that the products are manufactured pursuant to license. The LICENSED PRODUCTS or their packaging may also bear the statement "made by/for LICENSEE under license from the Massachusetts Institute of Technology, all rights reserved", and each LICENSED PRODUCT shall bear the notation " (R) " if registered for that class of goods or, if not registered for such class of goods, "TM" or other appropriate indication. Registrations are indicated in Appendix A.

10. INDEMNIFICATION AND INSURANCE

10.1 LICENSEE agrees that it is wholly responsible for all products manufactured or SOLD by or for it, including all LICENSED PRODUCTS, and that MIT shall have no liability for any items, including any LICENSED PRODUCT, manufactured or SOLD by or for LICENSEE. LICENSEE shall comply with all government regulations in the manufacture, advertisement, sale, or disposal of the LICENSED PRODUCTS.

10.2 LICENSEE shall indemnify, defend, and hold harmless MIT and its trustees, officers, faculty, students, employees, and agents and their respective successors, heirs and assigns (the "Indemnitees"), against any liability, damage, loss, or expense (including reasonable attorneys fees and expenses) incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, actions, demands or judgments arising out of any theory of liability (including without limitation actions in the form of tort, warranty, or strict liability and regardless of whether such action has any factual basis) concerning the use of any LICENSED MARK, or use, sale, manufacture, workmanship, material, design, or advertisement of any LICENSED PRODUCT, arising out of, directly or indirectly, the rights granted in this Agreement.

10.3 LICENSEE shall obtain and carry in full force and effect commercial general liability insurance, including product liability insurance, which shall protect LICENSEE and Indemnitees with respect to events covered by Paragraph 10.2 above. Such insurance (i) shall be issued by an insurer licensed to practice in the Commonwealth of Massachusetts or an insurer pre-approved by MIT, such approval not to be unreasonably withheld, (ii) shall list MIT as an additional insured thereunder, (iii) shall be endorsed to include product liability coverage, and (iv) shall require thirty (30) days written notice to be given to MIT prior to any cancellation or material change thereof.

The limits of such insurance shall not be less than One Million Dollars ($1,000,000) per occurrence with an aggregate of Two Million Dollars ($2,000,000) for bodily injury including death; and One Million Dollars ($1,000,000) per occurrence with an aggregate of Two Million Dollars ($2,000,000) for property damage. LICENSEE shall provide MIT with Certificates of Insurance evidencing compliance with this paragraph.

LICENSEE shall continue to maintain such insurance after the expiration or termination of this Agreement during any period in which LICENSEE continues to make, have made, or SELL a LICENSED PRODUCT under this Agreement.

11. ASSIGNMENT

This Agreement is personal to LICENSEE and may not be assigned without the prior written consent of MIT, which shall not be unreasonably withheld, and the assignee or transferee must agree in writing to MIT to be bound by the terms and conditions of this Agreement prior to such assignment or transfer.

12. PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

12.1 Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the parties:

All notices under this Agreement shall be deemed delivered when sent via confirmed electronic mail, or telecopier to the telefacsimile number identified above, or three (3) days after mailing via certified or registered mail, return receipt requested, postage prepaid, addressed to the party for whom intended, or when actually received by the party for whom intended, whichever is earlier. A party may change its contact information immediately upon written notice to the other party in the manner provided in this paragraph.

12.2 Any items (or packages thereof) to be shipped by LICENSEE to MIT shall be deemed sufficiently made or given on the date of receipt by MIT if such package or items are shipped prepaid via Federal Express, UPS, DHL or similar first class service to MIT at the address in Paragraph 12.1.

13. MISCELLANEOUS PROVISIONS

13.1 This Agreement shall be construed, governed, interpreted and applied in accordance with the internal laws of the Commonwealth of Massachusetts, U.S.A.

13.2 The parties hereto acknowledge that this Agreement sets forth the entire Agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument executed by the parties hereto.

13.3 The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.

13.4 The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.

IN WITNESS WHEREOF, the parties have caused this agreement to be executed by their duly authorized representatives.

KASAN_상표사용허락, 영업비밀실시, 기술이전 라이선스 계약서에서 제품판매 기록 및 보고, 위반 시 손해배상 책임

Tags : 계약조항샘플, 국제계약, 독점판매, 라이선스, 비독점계약, 상표라이센스, 상표사용허락, 영문계약, 통상사용권

작성일시 : 2019.06.13 16:00
Trackback 0 : Comment 0

상표사용허락, 영업비밀실시, 기술이전 라이선스 계약서에서 제품판매 기록 및 보고, 위반 시 손해배상 책임 등 국문계약 조항 샘플

제 0 조 판매기록 및 보고

1.1 유통판매보고.

‘라이센시’는 다음 규정에 따라 유통 사업에 대한 보고서를 ‘라이센서’에게 제출해야 한다:

(i) 수입제품에 대한 판매 및 재고에 관련 보고서는 각 달의 말일로부터 15일 이내에 매달 제출한다;

(ii) 수입제품(모든 제품의 항목별로) 판매, 재고 반품 및 공제내역(‘라이센서’의 승인에 따른 경우)에 대한 보고서가 각각의 계약연도 종결 후 30일 내에 제출되어야 한다.

(iii) 매 계약연도의 개시일자로부터 최소한 60일 전에 판매계획에 관련된 보고서를 계절별로 제출해야 한다.

1.2 라이선스제품 판매보고.

‘라이센시’는 다음 조항에 의거해서 라이선스 사업에 관한 자신의 보고서를 ‘라이센서’에 제출해야 한다:

(i) 라이선스 제품의 판매, 가공 및 재고에 관련된 보고서를 매 월말로부터 15일 이내에 매달 제출해야 한다

(ii) 라이선스 제품(모든 제품의 항목별로)의 판매, 가공, 재고, 반품 및 공제내역 관련된 보고서가 각각의 계약연도 종결 후 30일 내에 제출되어야 한다.

1.3 회계장부 및 감사

‘라이센시’는 자신의 비용으로 본 계약의 범주에 해당하는 거래를 포함한 완전하고 정확한 회계장부 및 기록을 자신의 주 사업장에 보관 및 유지해야 한다. 사전에 통보한 경우 ‘라이센서’ 또는 적법한 권한을 부여 받은 대리인은 ‘라이센시’의 업무 시간 중에 그 장부와 기록에 대해 감사할 수 있는 권리를 갖는다. ‘라이센시’의 장부와 기록에 대한 감사와 관련된 비용은 본 계약서에 달리 명시되지 않는 한 ‘라이센서’ 측에서 부담해야 한다. 만약 본 계약에 명시된 바와 같이 어떠한 감사로 인해 ‘라이센시’가 ‘라이센서’에게 보고한 수치들과 2%를 초과하는 불일치가 확인된 경우 ‘라이센서’의 요청에 따라 ‘라이센시’는 그러한 감사에 대한 모든 비용과 경비를 ‘라이센서’에게 배상해야 한다. 그것으로 인해 ‘라이센서’의 손해배상청구권 등 다른 권리가 제한되지 않는다.

제 0 조 품질관리

1.1 상표 이미지와 품질.

수입제품 및 라이선스 제품의 판매를 촉진하는 과정에서 ‘라이센시’는 상표에 대한 고객의 호의와 평판을 유지하고 촉진시켜야 하며, 제품의 이미지와 높은 수준의 품질을 유지하며, ‘라이센서’의 이익에 해로운 어떤 활동도 하면 안 된다.

1.2 저작권의 소유

수입제품, 라이선스 제품 및 노하우와 관련된 견본, 스케치 및 재료를 포함하고, 그에 대한 수정, 개선 또는 재생산을 포함하여 ‘라이센서’에 의해 창작된 도판, 디자인에 대한 모든 저작권 및 기타 권리, 소유권 및 이익에 대한 권리는 ‘라이센서’에 귀속되고 ‘라이센서’의 단독 재산임을 인정한다. ‘라이센서’의 요구에 따라 ‘라이센시’는 그러한 삽화 및 디자인에 대한 ‘라이센서’의 독점적 소유권을 확인하고 기록하기 위해 ‘라이센서’의 의견에 따라 수시로 필요로 할 수 있는 과제 및 기타 문서화 작업을 수행해야 한다. ‘라이센서’가 제작할 수 있는 삽화와 디자인은 자신의 사업지역 내에서 수입제품의 유통과 판매 및 라이선스 제품의 가공과 판매를 위해서만 ‘라이센시’에게 단독 및 독점적으로 제공된 것들이다. ‘라이센시’는 삽화, 디자인, 그리고 제품에 사용된 기타 재료에 관한 모든 저작권과 기타 통보 내용을 ‘라이센서’의 요청에 따라 표시해야 ‘라이센서’한다.

1.3 위반사실에 대한 통보.

‘라이센시’는 노하우에 대한 침해 또는 모방, 혹은 타인이 노하우와 혼동을 일으키도록 유사한 상표 혹은 거래명 등을 사용하는 것을 인지한 경우 ‘라이센서’에 즉시 서면으로 통보해야 한다. ‘라이센시’는 ‘라이센서’의 합리적 요청이 있을 경우 그러한 소송의 진행과 관련하여 ‘라이센서’에 협력해야 한다. 그러나, ‘라이센서’는 그러한 조치가 권장할 만한 것이 아닌 경우 그러한 조치를 취할 의무가 없다.

1.4 권리침해 금지.

‘라이센시’는 (a) 수입 제품의 유통, (b) 라이선스 제품의 제조, 광고, 홍보, 유통 및 판매, (c) 제품에 대한 제반 광고 및 판매촉진 및 (d) 그와 관련된 일체의 행위 과정에서 제3자 보유하는 저작권 및/또는 디자인권을 침해하는 어떠한 행동도 하여서는 안 된다.

제 0 조 손해배상.

1.1 ‘라이센시’의 손해배상.

‘라이센시’는 자신이 행위 또는 누락 사항으로 인하거나 이 계약에 따른 자신의 의무, 보증 또는 표현에 대한 위배를 발생시키는 행동에 의해 ‘라이센서’의 사무원, 감독관, 종업원 등을 상대로 하는 청구, 소송, 손실, 채무, 손해, 비용 및 경비(합리적인 변호사 비용 포함) 등에 대해 방어하고 배상하여 ‘라이센서’에 해가 되지 않도록 해야 한다. 본 조항의 효력은 본 계약이 종료 또는 해지된 이후에도 존속한다.

1.2 ‘라이센서’의 손해배상.

‘라이센서’는 자신이 행위 또는 누락 사항으로 인하거나 이 계약에 따른 자신의 의무, 보증 또는 표현에 대한 위배를 발생시키는 행동에 의해 ‘라이센시’의 사무원, 감독관, 종업원 등을 상대로 하는 청구, 소송, 손실, 채무, 손해, 비용 및 경비(합리적인 변호사 비용 포함) 등에 대해 방어하고 배상하여 ‘라이센시’에 해가 되지 않도록 해야 한다. 본 조항의 효력은 본 계약이 종료 또는 해지된 이후에도 존속한다.

1.3 책임제한.

어떤 경우라도 각 계약당사자는 본 계약 하에서 업무 수행 또는 업무 불이행의 결과로 나타난 상대방 계약당사자의 결과적, 부수적 또는 간접적 손해에 대해 책임을 지지 않는다; 계약, 이행 태만 또는 다른 어떠한 근거에 의한 경우인지 여부를 불문하고 그러하다(사업 이익에 대한 손실을 포함하되 그에 한정되지 않는다). 본 조항의 효력은 본 계약이 종료 이후에도 존속한다.

KASAN_국제계약, 영문계약 실무 - 상표사용허락 라이선스 계약서 조항 샘플.pdf

Tags : 계약위반, 계약조항샘플, 국제계약, 독점계약, 독점판매, 라이선스, 상표라이선스, 상표사용허락, 손해배상, 영업비밀, 판매기록보고, 회계장부감사

작성일시 : 2019.06.13 09:04
Trackback 0 : Comment 0

국제계약, 영문계약 실무 - 상표사용허락 라이선스 계약서 조항 샘플

TRADEMARK LICENSE AGREEMENT

THIS AGREEMENT is entered into the last date written below by and between [INSERT NAME OF LICENSOR, ENTITY TYPE, and ADDRESS] (“LICENSOR”), and [INSERT NAME OF LICENSEE, ENTITY TYPE, and ADDRESS] (“LICENSEE”).

WHEREAS, LICENSOR is the sole and exclusive owner of the following trademarks and registrations: [INSERT] (the “Trademarks”); and

WHEREAS, LICENSOR has the power and authority to grant to LICENSEE the right, privilege and license to use the Trademarks on or in association with the goods and/or services covered by the registrations (the “Licensed Products”); and

WHEREAS, LICENSEE has represented that it has the ability to manufacture, market and distribute the Licensed Products in [INSERT TERRITORY] (the "Territory") and to use the Trademarks on or in association with the Licensed Products; and

WHEREAS, LICENSEE desires to obtain from LICENSOR a license to use, manufacture, have manufactured and sell Licensed Products in the Territory and to use the Trademarks on or in association with the Licensed Products; and

WHEREAS, both LICENSEE and LICENSOR are in agreement with respect to the terms and conditions upon which LICENSEE shall use the Trademarks;

NOW, THEREFORE, in consideration of the promises and agreements set forth herein, the parties, each intending to be legally bound hereby, do promise and agree as follows.

1. LICENSE GRANT

A. LICENSOR hereby grants to LICENSEE a non-exclusive license to use the Trademarks on or in association with the Licensed Products in the [INSERT TERRITORY] (Territory), as well as on packaging, promotional and advertising material associated therewith.

B. LICENSOR hereby grants to LICENSEE the non-exclusive right and license to use, manufacture, have manufactured, sell, distribute, and advertise the Licensed Products in the Territory. It is understood and agreed that this license shall pertain only to the Trademarks and the Licensed Products and does not extend to any other mark, product or service.

C. LICENSEE may not grant any sublicenses to any third party without the prior express written consent of the LICENSOR which may be withheld for any reason.

2. TERM OF THE AGREEMENT

This Agreement and the provisions hereof, except as otherwise provided, shall be in full force and effect commencing on the last the date of execution below and shall extend for [INSERT LENGTH OF TERM] (the “Term”).

3. COMPENSATION

A. In consideration for the licenses granted hereunder, LICENSEE agrees to pay to LICENSOR a royalty of ____% (the “Royalty”) based on LICENSEE’s Net Sales of Licensed Products, accruing upon the sale of the Licensed Products (i.e., when the Licensed Product is billed, invoiced, shipped, or paid for, whichever is first regardless of the time of collection by LICENSEE), calculated on a quarterly calendar basis (the "Royalty Period") and shall be payable no later than thirty (30) days after the termination of the preceding full calendar quarter, i.e., commencing on the first (1st) day of January, April, July, and October, with late payments incurring interest at the rate of ONE PERCENT (1%) per month from the date such payments were originally due.

B. In the event that LICENSEE grants any previously approved sub-licenses for the use of the Trademarks in countries outside of the United States, LICENSEE shall pay LICENSOR FIFTY PERCENT (50%) of the gross income received by LICENSEE from such sub-licensees.

C. LICENSEE shall provide LICENSOR with a written royalty statement in a form acceptable to LICENSOR each Royalty Period whether or not any Licensed Products were sold during that Period and the receipt or acceptance by LICENSOR of any royalty statement or payment shall not prevent LICENSOR from subsequently challenging the validity or accuracy of such statement or payment.

D. "Net Sales" shall mean LICENSEE's gross sales (the gross invoice amount billed customers) of Licensed Products, less discounts and allowances actually shown on the invoice and less any bona fide returns. No other costs incurred in the manufacturing, selling, advertising, and distribution of the Licensed Products or any uncollectible accounts or allowances shall be deducted.

4. AUDIT

A. LICENSOR shall have the right, upon at least five (5) days written notice to inspect LICENSEE's books and records and all other documents and material in the possession of or under the control of LICENSEE with respect to the subject matter of this Agreement at a location in the United States. LICENSOR shall have free and full access thereto for such purposes and shall be permitted to make copies thereof and extracts therefrom.

B. In the event that such inspection reveals a discrepancy in the amount of Royalty owed LICENSOR from what was actually paid, LICENSEE shall pay such discrepancy, plus interest, calculated at the rate of ONE AND ONE-HALF PERCENT (1 1/2%) per month. In the event that such discrepancy is in excess of ONE THOUSAND UNITED STATES DOLLARS ($1,000.00), LICENSEE shall also reimburse LICENSOR for the cost of such inspection including any attorney's fees incurred in connection therewith.

C. All books and records relative to LICENSEE's obligations hereunder shall be maintained and kept accessible and available to LICENSOR for inspection in the United States for at least three (3) years after termination of this Agreement.

D. In the event that an investigation of LICENSEE's books and records is made, certain confidential and proprietary business information of LICENSEE may necessarily be made available to the person or persons conducting such investigation. It is agreed that such confidential and proprietary business information shall be retained in confidence by LICENSOR and shall not be used by LICENSOR or disclosed to any third party for a period of two (2) years from the date of disclosure, or without the prior express written permission of LICENSEE unless required by law. It is understood and agreed, however, that such information may be used in any proceeding based on LICENSEE's failure to pay its actual Royalty obligation.

5. WARRANTIES AND OBLIGATIONS

A. LICENSOR represents and warrants that it has the right and power to grant the licenses granted herein and that there are no other agreements with any other party in conflict herewith.

B. LICENSOR further represents and warrants that to the best of its knowledge, the Trademarks do not infringe any valid right of any third party.

C. LICENSEE represents and warrants that it will use its best efforts to promote, market, sell, and distribute the Licensed Products.

D. LICENSEE shall be solely responsible for the manufacture, production, sale, and distribution of the Licensed Products and will bear all related costs associated therewith.

E. It is the intention of the parties that LICENSEE shall introduce the Licensed Products in all countries in the Territory on or before [INSERT DATE]. Failure to meet this deadline shall constitute grounds for immediate termination of this Agreement by LICENSOR.

6. NOTICES, QUALITY CONTROL AND SAMPLES

A. The licenses granted hereunder are conditioned upon LICENSEE's full and complete compliance with the marking provisions of the patent, trademark and copyright laws of the United States and other countries in the Territory.

B. The Licensed Products, as well as all promotional, packaging, and advertising material relative thereto, shall include all appropriate legal notices as required by LICENSOR. [INSERT REQUIRED NOTICE].

C. The Licensed Products shall be of a high quality which is at least equal to comparable products previously manufactured and marketed by LICENSEE under the trademarks and in conformity with a standard sample approved by LICENSOR.

D. If the quality of a class of the Licensed Products falls below such a production-run quality, as previously approved by LICENSOR, LICENSEE shall use its best efforts to restore such quality. In the event that LICENSEE has not taken appropriate steps to restore such quality within thirty (30) days after notification by LICENSOR, LICENSOR shall have the right to terminate this Agreement and require that the LICENSEE cease using the Trademarks.

E. Prior to the commencement of manufacture and sale of the Licensed Products, LICENSEE shall submit to LICENSOR, at no cost to LICENSOR and for approval as to quality, six (6) sets of samples of all Licensed Products which LICENSEE intends to manufacture and sell and one (1) complete set of all promotional and advertising material associated therewith. Failure of LICENSOR to approve such samples within thirty (30) working days after receipt thereof will be deemed approval. Once such samples have been approved by LICENSOR, LICENSEE shall not materially depart therefrom without LICENSOR's prior express written consent, which shall not be unreasonably withheld.

F. At least once during each calendar year, LICENSEE shall submit to LICENSOR, for approval, an additional six (6) sets of samples.

G. The LICENSEE agrees to permit LICENSOR or its representative to inspect the facilities where the Licensed Products are being manufactured and packaged.

7. NOTICE AND PAYMENT

A. Any notice required to be given pursuant to this Agreement shall be in writing and delivered personally to the other designated party at the above stated address or mailed by certified or registered mail, return receipt requested or delivered by a recognized national overnight courier service, except e-mail may be used for day-to-day operations and contacts but not for ‘notice’ or other communications required under this agreement or by law.

B. Either party may change the address to which notice or payment is to be sent by written notice to the other in accordance with the provisions of this paragraph.

8. PATENTS, TRADEMARKS AND COPYRIGHTS

A. LICENSOR shall seek, obtain and, during the Term of this Agreement, maintain in its own name and at its own expense, appropriate protection for the Trademarks, and LICENSOR shall retain all right, title and interest in the Trademarks as well as any modifications made to the Trademarks by LICENSEE. LICENSEE agrees that its use of the Trademarks inures to the benefit of LICENSOR and that the LICENSEE shall not acquire any rights in the Trademarks.

B. The parties agree to execute any documents reasonably requested by the other party to effect any of the above provisions.

C. LICENSEE acknowledges LICENSOR's exclusive rights in the Trademarks and, further, acknowledges that the Trademarks are unique and original to LICENSOR and that LICENSOR is the owner thereof. LICENSEE shall not, at any time during or after the effective Term of the Agreement dispute or contest, directly or indirectly, LICENSOR's exclusive right and title to the Trademarks or the validity thereof. LICENSOR, however, makes no representation or warranty with respect to the validity of any patent, trademark or copyright which may issue or be granted therefrom.

9. TERMINATION OR EXPIRATION

A. In addition to the termination rights that may be provided elsewhere in this Agreement, either party may terminate this Agreement upon thirty (30) days written notice to the other party in the event of a breach of a material provision of this Agreement by the other party, provided that, during the thirty (30) day period, the breaching party fails to cure such breach. Upon expiration or termination, all Royalty obligations, including any unpaid portions of the Guaranteed Minimum Royalty, shall be accelerated and shall immediately become due and payable, and LICENSEE's obligations for the payment of a Royalty and the Guaranteed Minimum Royalty shall survive expiration or termination of this Agreement and will continue for so long as LICENSEE continues to manufacture, sell or otherwise market the Licensed Products.

B. Upon expiration or termination, LICENSEE shall provide LICENSOR with a complete schedule of all inventory of Licensed Products then on-hand (the "Inventory").

C. Upon expiration or termination, except for reason of a breach of LICENSEE's duty to comply with the quality control or legal notice marking requirements, LICENSEE shall be entitled, for an additional period of three (3) months and on a nonexclusive basis, to continue to sell such Inventory. Such sales shall be made subject to all of the provisions of this Agreement and to an accounting for and the payment of a Royalty thereon, due and paid within thirty (30) days after the close of the three (3) month period.

D. Upon the expiration or termination of this Agreement, all of the rights of LICENSEE under this Agreement shall terminate and immediately revert to LICENSOR and LICENSEE shall immediately discontinue all use of the Trademarks at no cost whatsoever to LICENSOR, and LICENSEE shall immediately return to LICENSOR all material relating to the Trademarks including at no cost to LICENSOR.

10. GOOD WILL

LICENSEE recognizes the value of the good will associated with the Trademarks and acknowledges that the Trademarks and all rights therein including the good will pertaining thereto, belong exclusively to LICENSOR.

11. INFRINGEMENTS

If an action for infringement of the rights licensed in this Agreement is brought, each party shall execute all papers, testify on all matters, and otherwise cooperate in every way necessary and desirable for the prosecution of any such lawsuit.

12. INDEMNITY

LICENSEE agrees to defend and indemnify LICENSOR, its officers, directors, agents and employees, against all costs, expenses and losses (including reasonable attorneys' fees and costs) incurred through claims of third parties against LICENSOR based on the manufacture or sale of the Licensed Products including, but not limited to, actions founded on product liability.

13. INSURANCE

LICENSEE shall, throughout the Term of the Agreement, obtain and maintain at its own cost and expense from a qualified insurance company licensed to do business in California, standard Product Liability Insurance naming LICENSOR as an additional named insured. Such policy shall provide protection against any and all claims, demands and causes of action arising out of any defects or failure to perform, alleged or otherwise, of the Licensed Products or any material used in connection therewith or any use thereof. The amount of coverage shall be a $10 million combined single limit for each single occurrence for bodily image and/or property damage. The policy shall provide for ten (10) days notice to LICENSOR from the insurer by Registered or Certified Mail, return receipt requested, in the event of any modification, cancellation or termination thereof. LICENSEE agrees to furnish LICENSOR a certificate of insurance evidencing same within thirty (30) days after execution of this Agreement and, in no event shall LICENSEE manufacture, distribute or sell the Licensed Products prior to receipt by LICENSOR of such evidence of insurance.

14. JURISDICTION AND DISPUTES

A. This Agreement shall be governed in accordance with the laws of the State of California, United States of America.

B. Any controversy, claim or dispute arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate (except at the option of either party for any application for injunctive relief) shall be finally settled by arbitration in Los Angeles County, California under the rules of the American Arbitration Association (AAA) before one arbitrator and judgment upon the award rendered may be entered in any court having jurisdiction. In this regard, the parties submit to the personal subject matter jurisdiction of the State of California. The arbitration provisions of this Section shall be interpreted according to, and governed by, the Federal Arbitration Act, and any action to enforce any rights hereunder shall be brought exclusively in the U.S. District Court for the Central District of California. EACH PARTY HERETO KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT TO A TRIAL BY JURY OF ANY DISPUTE RELATING TO THIS AGREEMENT AND AGREES THAT ANY SUCH ACTION SHALL BE ADJUDICATED BY AN ARBITRATOR AND WITHOUT A JURY.

C. The parties may mutually agree upon any procedure for appointing the arbitrator and shall inform the AAA administrator as to such procedure; however, if within 45 days after the commencement of the arbitration, all of the parties have not mutually agreed on a procedure for appointing the arbitrator or have not mutually agreed on the designation of the arbitrator, the AAA administrator shall unilaterally appoint and designate the presiding arbitrator.

D. If a party fails to file a statement of defense within the time established by the tribunal without showing sufficient cause for such failure, as determined by the tribunal, or if a party, duly notified, fails to appear at a hearing without showing sufficient cause for such failure, as determined by the tribunal, the tribunal may proceed with the arbitration; or if a party, duly invited to produce evidence or take any other steps in the proceedings fails to do so within the time established by the tribunal without showing sufficient cause for such failure, as determined by the tribunal, the tribunal may make the award on the evidence before it.

E. The arbitrator may, in the Award, allocate all or part of the costs of the arbitration, including the fees of the arbitrator and the reasonable attorneys’ fees of the prevailing party.

15. AGREEMENT BINDING ON SUCCESSORS

The provisions of this Agreement shall be binding on and shall inure to the benefit of the parties hereto, and their heirs, administrators, successors, and assigns.

16. WAIVER

No waiver by either party of any default shall be deemed as a waiver of prior or subsequent default of the same or other provisions of this Agreement.

17. SEVERABILITY

If any term, clause, or provision hereof is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity or operation of any other term, clause or provision and such invalid term, clause or provision shall be deemed to be severed from the Agreement.

18. NO JOINT VENTURE

Nothing contained herein shall constitute this arrangement to be employment, a joint venture or a partnership.

19. ASSIGNABILITY

The license granted hereunder is personal to LICENSEE and shall not be assigned by any act of LICENSEE or by operation of law unless in connection with a transfer of substantially all of the assets of LICENSEE or with the consent of LICENSOR.

20. GOVERNMENTAL APPROVAL

As promptly as possible after execution of this Agreement, LICENSEE agrees to submit copies of this Agreement to any governmental agency in any country in the Territory where approval of a license agreement is necessary and agrees to promptly prosecute any such application diligently. This Agreement shall only become effective in such country or countries upon receipt of appropriate approval from the applicable governmental agency.

21. INTEGRATION

This Agreement constitutes the entire understanding of the parties, and revokes and supersedes all prior agreements between the parties, including any option agreements which may have been entered into between the parties, and is intended as a final expression of their Agreement. It shall not be modified or amended except in writing signed by the parties hereto and specifically referring to this Agreement. This Agreement shall take precedence over any other documents which may be in conflict with said Agreement.

22. AMENDMENTS

Any amendment to this Agreement must be in writing and signed by an authorized person of each party.

IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have each caused to be affixed hereto its or his/her hand and seal the day indicated.

[INSERT NAME OF LICENSOR] [INSERT NAME OF LICENSEE]

By: By:

Title: Title:

Date: Date:

KASAN_상표사용허락, 영업비밀실시, 기술이전 라이선스 계약서에서 상표사용 허락 및 제품판매관련 계약조항 샘플.p

Tags : 계약위반, 계약조항샘플, 국제계약, 기술이전, 독점판매, 라이선스, 상표사용허락, 영문계약, 영업비밀

작성일시 : 2019.06.13 08:27
Trackback 0 : Comment 0

상표사용허락, 영업비밀실시, 기술이전 라이선스 계약서에서 상표사용 허락 및 제품판매관련 계약조항 샘플

제 0 조 제품판매 관련 라이센시의 의무

1.1 판촉활동

‘라이센시’는 자신의 비용으로 최상의 판매 성장 활동과 적절한 판매 증가를 보장할 수 있는 효율적인 판매 조직을 구성하고 유지하여 자신의 사업지역 내에서 제품의 판매를 촉진하고, 제품의 수요증가와 시장 점유 증가를 위해 합리적인 노력을 다해야 한다.

1.2 광고

양 계약당사자들은 사업지역 내에서 광고 및 대중 홍보를 통해 제품의 높은 기준과 품질에 대한 대중의 평판과 이미지 형성의 중요성에 대해 인식하고 동의한다. ‘라이센시’는 사업지역 내에서 제품의 광고(판촉 캠페인, 카탈로그 배포, 전시장 전시, 언론 보도와 일반 및 산업용 잡지에서 광고 포함)에 최선을 다해야 한다. ‘라이센시’의 광고 및 홍보 과정에서 ‘라이센시’는 그러한 광고나 판촉 캠페인 전에 그러한 광고 및 홍보에 관한 정보를 ‘라이센서’에게 제공할 수 있다.

1.3 매장

‘라이센시’는 자신의 비용으로 ‘라이센서’와 사전에 상의하여 인터넷 매장을 포함한 매장(각각은 “매장”, 복수로는 “매장들”이라 함)을 수입 제품과 라이선스 제품 판매를 위한 적절한 장소에 열어야 한다. 본 계약의 계약기간 동안 각 계약연도에, ‘라이센시’는 첨부목록-E에 기재된 일정에 따른 수의 매장을 열고 유지하여야 한다.

1.4 재고

‘라이센시’는 자신의 사업지역 내에서 예측되는 수요량에 부합되도록 적정한 제품 재고를 유지해야 한다.

1.5 신용유지

‘라이센시’는 자신의 사업지역 내에서 제품 및 제품에 대한 고객의 신용을 유지하고 향상시켜야 한다.

1.6 상표 이미지와 품질 유지

수입제품 및 라이선스 제품의 판매를 촉진하는 과정에서 ‘라이센시’는 상표에 대한 고객의 호의와 평판을 유지하고 촉진시켜야 하며, 제품의 이미지와 높은 수준의 품질을 유지하며, ‘라이센서’의 이익에 해로운 어떤 활동도 하면 안 된다.

11.7 상표의 사용방식

‘라이센시’는 표지, 문서 또는 자료에서, 사전에 ‘라이센서’에게 통보를 한 후에, 상표를 다른 이름, 마크 또는 로고와 관련하여 또는 함께 사용할 수 있고 다른 이름, 마크 또는 로고에 근접하게 표시할 수 있다.

1.8상표사용 관련 규칙

‘라이센서’는 필요한 경우 대중에 제시하기 위해 상표의 사용방식에 관련된 합리적인 규칙과 규정을 발표할 수 있다.

1.9법규준수

‘라이센시’는 자신의 사업지역 내에서 제품의 유통, 판매 및 판촉에 적용되는 모든 현지 법규, 규칙, 규정과 요건을 준수해야 한다.

1.10 판매비용

판매에 대한 모든 비용과 제품과 관련된 전체 비용은 본 계약에 명확히 언급된 것을 제외하고 모두 ‘라이센시’가 부담하기로 한다. ‘라이센시’는 ‘라이센서’의 사전 서면 승인 없이 ‘라이센서’ 측에 부과될 비용을 발생시켜서는 안 된다.

1.11 라이센시의 사업지역 제한

‘라이센시’는 자신의 사업지역 외부에서 고객에게 판매 또는 고객 확보나 제품의 대규모 유통 창고 또는 일반 창고를 유지해서는 안되며, 제품의 판매 또는 유통을 위한 지점을 설치해서도 안 된다.

‘라이센시’ 자신의 사업지역 외부에서 판매 또는 유통을 위해 제품을 구매하거나 시도한다고 믿거나 믿을 만한 이유가 있다고 판단되는 고객에게 제품을 판매해서는 안 된다. (그러한 고객을 ‘전용자’라고 칭한다) 만일 ‘라이센시’가 인지한 상태에서 ‘전용자’에게 제품을 판매한 경우, ‘라이센서’에게 15.2 항의 규정에 의거하여 본 계약을 종료할 수 있는 권리가 발생하게 된다.

‘라이센시’는 수시로 ‘라이센서’의 요청이 있으면 ‘전용자’의 위치를 파악하고 식별할 수 있도록 최선을 다해야 하며, 그러한 ‘전용자들’에 대한 적절한 조치를 취해야 한다.

‘라이센시’가 ‘라이센서’가 대상 브랜드에 대한 상표권을 보유하고 있는 사업지역의 밖에서 제품을 판매하거나 유통하고자 하는 경우, ‘라이센시’는 ‘라이센서’와 그러한 판매나 유통에 대하여 ‘라이센서’가 그러한 판매나 유통의 과정에 관여하여야 한다는 조건을 전제로 협상을 할 수 있다. 의문을 없애기 위해 부연하자면, 그러한 판매 또는 유통은 ‘라이센서’와 ‘라이센시’ 사이에 그에 대한 모든 조건이 합의되기 전에는 개시될 수 없다.

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 면책조항 Indemnificati

Tags : 계약위반, 계약조항샘플, 국제계약, 기술이전, 노우하우제공, 독점계약, 독점판매, 라이선스, 상표사용허락, 영업비밀

작성일시 : 2019.06.12 13:00
Trackback 0 : Comment 0

기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 면책조항 Indemnification 계약조항 샘플

15. MUTUAL INDEMNIFICATION AND INSURANCE.

15.1 Licensor’s Right to Indemnification.

Subject to the provisions of this Agreement, Licensee shall indemnify, defend and hold harmless Licensor and its Affiliates, and their respective employees, officers, independent contractors, consultants or agents, and their respective successors, heirs and assigns and representatives (the “Licensor Indemnitees”), from and against any and all claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs (including without limitation reasonable legal expenses, costs of litigation and reasonable attorneys’ fees) or judgments, whether for money or equitable relief, of any kind (“Losses and Claims”), to the extent arising out of or relating to, directly or indirectly:

(a) the negligence, recklessness or wrongful intentional acts or omissions of Licensee, its Affiliates and/or its Sublicensees and its or their respective employees, officers, independent contractors, consultants or agents, in connection with Licensee’s performance of its obligations or exercise of its rights under this Agreement;

(b) any breach by Licensee of any representation, warranty, covenant or obligation set forth in this Agreement; and/or

(c) the Development and/or Commercialization (including, without limitations, the promotion, advertising, offering for sale, sale or other disposition), transfer, importation or exportation, labeling, handling storage, use of, exposure to any Licensed Products actually conducted by or for Licensee or any of its Affiliates, Sublicensees, agents and independent contractors (in each case, excluding any Development, Manufacture or Commercialization activities carried out by and/or on behalf of Licensor either within the Territory or outside the Territory); except in each such case for Losses and Claims to the extent reasonably attributable to any negligence, recklessness, wrongful or intentional acts or omissions, or breach of this Agreement by Licensor or a Licensor Indemnitee.

15.2 Licensee’s Right to Indemnification.

Subject to the provisions of this Agreement, Licensor shall indemnify, defend and hold harmless Licensee and its Affiliates, and their respective employees, officers, independent contractors, consultants or agents, and their respective successors, heirs and assigns and representatives (the “Licensee Indemnitees”), from and against any and all Losses and Claims, to the extent arising out of or relating to, directly or indirectly:

(a) the negligence, recklessness or wrongful intentional acts or omissions of Licensor, its Affiliates and/or its Sublicensees and its or their respective employees, officers, independent contractors, consultants or agents, in connection with Licensor’s performance of its obligations or exercise of its rights under this Agreement;

(b) any breach by Licensor of any representation, warranty, covenant or obligation set forth in this Agreement; and/or

(c) the Development and/or Commercialization (including without limitation promotion, advertising, offering for sale, sale or other disposition), transfer, importation or exportation, labeling, handling storage, use of, exposure to any Licensed Products actually conducted by or for Licensor or any of its Affiliates, Sublicensees, agents and independent contractors within or outside the Territory (in each case, excluding any Development or Commercialization activities carried out by Licensee or on behalf of Licensee at ALLERGAN’s direction hereunder either within or outside the Territory; provided that, notwithstanding anything to the contrary, Development or Commercialization activities commenced or performed before the Closing Date shall not be considered activities carried out by, for or on behalf of Licensee for the purposes of this indemnification obligation);

(d) subject to Section 15.5, the practice of the Licensed Intellectual Property in connection with the Licensed Products violates, infringes upon, or misappropriates the intellectual property rights of any Third Party; and

(e) personal injury or death, or any damage to any property, was caused by a defect in any Licensed Products manufactured by or for Licensor; except in each such case for Losses and Claims to the extent reasonably attributable to any negligence, recklessness, wrongful or intentional acts or omissions, or breach of this Agreement by Licensee or an Licensee Indemnitee.

15.3 Process for Indemnification.

A Party’s obligation to defend, indemnify and hold harmless the other Party under this Article 13 shall be conditioned upon the following:

(a) A Party seeking indemnification under this Article (the “Indemnitee”) shall give prompt written notice of the claim to the other Party (the “Indemnitor”). Failure to promptly notify the Indemnitor of any such claim shall not relieve the Indemnitor of any such duty to so indemnify except to the extent that the Indemnitor can demonstrate actual loss and prejudice as a result of such failure.

(b) Each Party shall furnish promptly to the other Party copies of all papers and official documents received in respect of any Losses and Claims. Failure to promptly furnish the other Party with such papers and official documents shall not relieve the other Party of any duty to indemnify except to the extent that the other Party can demonstrate actual loss and prejudice as a result of such failure. The Indemnitee shall cooperate as requested by the Indemnitor in the defense against any Losses and Claims.

(c) The Indemnitor shall have the right to assume and control the defense of the indemnification claim, including any settlement of such claim, at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee. The Indemnitee may participate in and monitor such defense with counsel of its own choosing at its sole expense. The Indemnitor shall not settle or compromise the indemnification claim in any manner which would have an adverse effect on the Indemnitee’s interests (including without limitation in relation to the scope or enforceability of the Licensor Patent Rights or Licensor Know-How, or Confidential Information or Patent or other rights licensed to Licensee by Licensor hereunder), without the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld, delayed or conditioned. The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor’s expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee.

(d) If the Indemnitor does not assume and conduct the defense of the claim as provided above, (i) the Indemnitee may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such claim in any manner the Indemnitee may deem reasonably appropriate (and the Indemnitee need not consult with, or obtain any consent from, the Indemnitor in connection therewith), and (ii) the Indemnitor shall remain responsible to indemnify the Indemnitee as provided in this Article.

15.4 Insurance.

(a) During the Term and for three (3) years thereafter, Licensee, at its sole expense, shall maintain such types and amounts of insurance coverage relating to product liability (including without limitation, premises operations, completed operations and broad form contractual liability) that is comparable in type and amount to the insurance customarily maintained by pharmaceutical companies with respect to similar prescription pharmaceutical products that are marketed, distributed and sold, and which names Licensor as an additional insured Party, as its interests may appear.

(b) During the Term and for three (3) years thereafter, Licensor, at its sole expense, shall maintain such types and amounts of insurance coverage relating to product liability (including without limitation, premises operations, completed operations and broad form contractual liability) that is comparable in type and amount to the insurance customarily maintained by pharmaceutical companies with respect to similar prescription pharmaceutical products that are marketed, distributed and sold, and which names Licensee as an additional insured Party, as its interests may appear.

15.5 Limitation on Certain Indemnities.

Notwithstanding Licensor’s indemnification obligations under Section 15.2, in the event of Losses and Claims arising out of Section 15.2(d), Licensee shall recover from Licensor such Losses and Claims from fifty percent (50%) of the sum of all payments made by Licensee to Licensor prior to the date of the award of such Losses and Claims, not including the Up-Front Payment pursuant to Section 8.1, and, in the event that such awarded Losses and Claims exceed such amount, Licensee may deduct any such excess Losses and Claims from payments due by Licensee to Licensor after the date of the award of such Losses and Claim, up to a maximum of fifty percent (50%) of each such payment, until Licensee has been compensated in full for all such awarded Losses and Claims.

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 국제계약, 영문계약 실무상 기본용어 설명 참고자료 – cov

Tags : indemnification, 계약분쟁, 계약위반, 국제계약, 기술이전, 라이선스, 면책조항, 영문계약, 책임제한

작성일시 : 2019.06.11 13:00
Trackback 0 : Comment 0

기술이전, 라이선스, 특허실시, 공동연구개발 국제계약, 영문계약 실무상 기본용어 설명 참고자료 – covenant, representation, warranty 의미, 위반책임 및 차이점

A covenant is a promise by a party by which it pledges that something is either done, will be done or shall not be done.

• Example 1: “Licensee shall pay Licensor a flat royalty based on 2.5% of Gross Revenues received from the sale of Licensed Products.”

• Example 2: “Company A hereby covenants not to sue Company B under any patent listed in Exhibit A for infringement based upon any act by Company B of manufacture, use, sale, offer for sale or import that occurs after the Effective Date.”

A representation is a statement of fact that induces a party to enter into the contract. The statement, made before or at the time of making the contract, regards a past fact or existing circumstance related to the contract which influences such party to enter the contract.

• Example 1: “Licensor represents to Licensee that it has the full and unencumbered right, power and authority to enter into this Agreement and to grant the license rights granted by Licensor to Licensee hereunder.

• Example 2: “Company A hereby represents that it owns full legal and equitable title to each patent listed in Exhibit A.”

A warranty is an undertaking or stipulation that a certain fact in relation to the subject of the contract is or shall be as it is stated or promised; and refers to an agreement to protect the recipient against loss if the fact is or becomes untrue (i.e., an implied indemnification).

• Example 1: “Licensor warrants to Licensee that it has not received any written notice or claim, and is not otherwise aware that the Licensed Technology infringes or misappropriates the proprietary rights of any other Person.”

• Example 2: “Company A warrants to Company B that the Technical Information provided hereunder will be the same as that used in the design, production, installation, and maintenance of Licensed Products produced in its own factories.”

A claim for breach of a covenant may be for damages or specific performance. When a breach of a covenant is “material” (i.e., a breach that destroys the value of the contract for the non-breaching party), however, it excuses the non-breaching party’s performance. This often is subjective and can be expensive to prove in later litigation. (Thus, the more specificity drafted into a contract – i.e., a listing of the specific and most-likely events that trigger a termination event – the better that contract protects the parties.)

Upon a false representation (or misrepresentation), however, the defrauded party may elect to void the entire contract and recover any sums paid.

When a breach of warranty occurs, the damages recoverable are the difference in the value as warranted (i.e., how they should have been) and the value as received.

This is because “representations” should be statements made by a party after investigation and with a belief that such statements are true, and “warranties” should be statements a party makes while willing to accept financial responsibility if the statement turns out to be untrue, regardless of whether they actually (or should have) investigated.

In sum, upon a breach of a covenant or breach of warranty, the contract remains binding and damages only are recoverable for the breach; whereas, upon a misrepresentation, the defrauded party may elect to void the entire contract.

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 TAX 세무조항, RECORD,

Tags : Covenant, representation, warranty, 계약위반, 국제계약, 기술이전, 라이선스, 영문계약, 영문계약용어

작성일시 : 2019.06.10 11:00
Trackback 0 : Comment 0

기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 TAX 세무조항, RECORD, AUDIT 회계자료 감사권한 관련 계약조항 샘플

Taxes; Withholding.

Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement.

In the event that any payment under this Agreement becomes subject to withholding taxes, other than income tax, under Applicable Laws, the payor may withhold from the payment the amount of such taxes due.

Payor will timely pay to the proper governmental authority the amount of any taxes withheld and will provide the payee with an official tax certificate or other evidence of tax obligation together with proof of payment from the relevant governmental authority sufficient to enable payee to claim such payment of taxes.

The Parties agree to cooperate with one another and use reasonable efforts to minimize or eliminate such tax withholding or similar obligations in respect of royalties, milestone payments, and any other payments made by Licensee to Licensor under this Agreement. The Parties shall, wherever possible, endeavour and cooperate to minimize the taxes due under this Agreement.

Records; Audits.

Licensee and its Affiliates will maintain, and Licensee will cause each of its Sublicensees, if any, to maintain, complete and accurate records in sufficient detail to confirm the accuracy of the calculation of royalty payments and the achievement of milestone events, for a period of three (3) years after the Calendar Year in which such sales or events occurred or for the period required under the Applicable Laws, whichever is longer.

Upon reasonable prior notice and without disruption to Licensee’s business, such records of Licensee and its Affiliates and Sublicensees shall be made available during regular business hours for a period of three (3) years from the end of the Calendar Year to which they pertain for examination, and not more often than once each Calendar Year, by an independent certified public accountant among the major internationally reputable accounting firms selected by Licensor, for the sole purpose of and only to the extent necessary for verifying the accuracy of the financial reports furnished by Licensee pursuant to this Article 8.

Such independent accountant shall disclose to Licensor only the amounts that such independent accountant believes to be due and payable hereunder to Licensor, details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit.

Any and all records examined by such independent accountant shall be deemed Licensee’s Confidential Information which may not be disclosed by such independent accountant to any Third Party, and Licensee may require such independent accountant to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less protective than those set forth in Article 16.

If, as a result of any inspection of the books and records of Licensee, it is shown that payments under this Agreement were less than the amount which should have been paid, then Licensee shall make all payments required to be made plus interest (as set forth in Section 8.7) from the original due date to eliminate any discrepancy revealed by such inspection within thirty (30) days.

If, as a result of any inspection of the books and records of Licensee, it is shown that payments under this Agreement were more than the amount which should have been paid, then Licensor shall, at Licensee’s election, either make all payments required to be made to eliminate any discrepancy revealed by such inspection within ninety (90) days or credit such amounts to Licensee against future payments.

Licensor shall pay for such audits, except that in the event that the audited amounts were underpaid by Licensee by more than five percent (5%) of the undisputed amounts that should have been paid during the period in question as per the audit, Licensee all pay the costs of the audit.

KASAN_독점라이선스 국제계약서에서 계약종료 시 라이센시의 보상청구 관련 주요내용, 분쟁사례, 판결 및 중재판정

Tags : audit, Tax, 계약위반, 계약조항샘플, 국제계약, 기술이전, 라이선스, 세무조항, 영문계약, 회계감사

작성일시 : 2019.06.10 09:16
Trackback 0 : Comment 0

독점라이선스 국제계약서에서 계약종료 시 라이센시의 보상청구 관련 주요내용, 분쟁사례, 판결 및 중재판정 요지 및 실무적 포인트 몇 가지

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 등 국제계약서, 영문계약서에서 미국법 FCPA, Anti-C

Tags : 계약위반, 계약종료, 공정거래법, 국제계약, 기술이전, 독점계약, 라이선스, 라이센시, 보상청구, 영문계약

작성일시 : 2019.06.05 17:00
Trackback 0 : Comment 0

기술이전, 라이선스, 특허실시, 공동연구개발 등 국제계약서, 영문계약서에서 미국법 FCPA, Anti-Corruption, Compliance 관련 계약조항 샘플

4.1. Compliance with Legal Requirements.

Licensee shall conduct, and shall ensure that its Affiliates, Sublicensees and Subcontractors, conduct, all activities hereunder, including all Development and Commercialization of the Product, in compliance with all Applicable Laws.

In addition, Licensee hereby certifies that (i) to its reasonably knowledge or belief, neither Licensee nor its Affiliates has been, prior to the Effective Date debarred under United States law, including Section 21 U.S.C. 335a (or any foreign equivalent thereof), and (ii) neither Licensee nor its Affiliates will, from and after the Effective Date, employ or otherwise use in any capacity, the services of any Person, who to the knowledge or belief of Licensee or any of its Affiliates is, debarred under United States law, including Section 21 U.S.C. 335a (or any foreign equivalent thereof) to perform any portion of the activities hereunder, including any Development and Commercialization of the Product.

Licensee shall notify Sub-Licensor in writing promptly upon becoming aware of any such debarment of any such Person, and shall, upon becoming so aware, promptly remove such Person from performing any such activities and from any function or capacity related to any such activities.

4.2. Compliance with Ethical Business Practices.

(a) Compliance with Laws and Policies.

Licensee shall conduct the activities contemplated herein, and shall ensure that its Affiliates, Sublicensees and Subcontractors, conduct the activities contemplated herein, in a manner which is consistent with all Applicable Laws in Korea including, as applicable, Good Clinical Practices, Good Laboratory Practices, the U.S. Foreign Corrupt Practices Act which generally prohibits the promise, payment or giving of anything of value either directly or indirectly to any Official for the purpose of obtaining or retaining business or any improper advantage, and the UK Bribery Act of 2010 which additionally includes the prohibition on the making of any bribe to a foreign public official with the intention of influencing such person in order to obtain or retain business or an advantage in the conduct of business, and good business ethics.

(b) Governments and International Public Organizations.

Licensee warrants that, in connection with this Agreement and Licensee’s business relating thereto, Licensee, its directors, employees, officers, and anyone acting on Licensee’s behalf or with Licensee’s knowledge, shall not offer, make or promise any payment, and shall ensure that its Affiliates, Sublicensees and Subcontractors, do not offer, make or promise any payment (either directly or indirectly, of money or other assets) to any government officials (including any government-owned or controlled commercial enterprise), or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing (hereinafter collectively referred as “Officials”) where such payment (either directly or indirectly of money or other assets) would constitute a violation of any Applicable Law.

In addition, Licensee shall make no payment (either directly or indirectly of money or other assets), and shall ensure that its Affiliates, Sublicensees and Subcontractors, make no payment in connection with this Agreement or Licensee’s business relating thereto, either directly or indirectly to Officials if such payment (either directly or indirectly of money or other assets) is for the purpose of (i) influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of either Party’s business; (ii) inducing such Official to do or omit to do any action in violation of the lawful duty of such Official; (iii) securing any improper advantage; or (iv) inducing such Official to use his/her position to affect or influence any decisions or actions of government or any legislative, administrative, public agency or other public body with respect to any activities undertaken relating to this Agreement.

Additionally, Licensee will make reasonable efforts to comply with requests for information, including answering questionnaires and narrowly tailored audit inquiries, to the extent they relate to the subject of this Agreement, to enable Licensor to ensure compliance with any applicable anti-corruption laws.

(c) Disclosure.

Where Licensor requests reasonable information regarding disclosure of any officers, employees, owners, or persons directly or indirectly retained by Licensee who are Officials or relatives of Officials of any governmental authority with oversight over the performance of Licensee’s obligations under this Agreement or any Regulatory Documentation, if such persons are engaged to perform Licensee’s obligations under this Agreement, Licensee shall provide complete and accurate information and documentation to Licensor with respect thereto. Licensee shall update such disclosures upon request of Licensor from time to time as necessary to ensure the information provided remains complete and accurate for the Term of this Agreement.

(d) Books and Records.

Licensee represents, warrants and covenants that all books, records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete and accurate and reflect in reasonable detail the character and amount of transactions and expenditures. Licensee further represents, warrants and agrees that no “off the books” or similar funds will be maintained or used in connection with this Agreement.

(e) Compliance Training.

Licensee agrees to ensure that all of Licensee’s employees involved in performing the obligations under this Agreement are made specifically aware of the compliance requirements under Sections 4.2(a), (b), (d), (e) and (f).

(f) Exclusions Lists.

Licensee shall not use (and shall cause its Affiliates not to use) any Person (including any employee, officer, director, Sublicensee or Third Party contractor) who is (or has been) on the Exclusions List, or who is (or has been) in Violation, in the performance of any activities hereunder. Licensee certifies to Sub-Licensor that as of the Effective Date, Licensee has screened itself, and its officers and directors (and its Affiliates, Sublicensees and Third Party contractors and their respective officers and directors) against the Exclusions Lists and that it has informed Licensor whether Licensee, or any of its officers or directors (or any of its Affiliates, Sublicensees or Third Party contractors or any of their respective officers and directors) has been in Violation. After the Effective Date, Licensee shall notify Licensor in writing immediately if any such Violation occurs or comes to its attention.

(g) Obligation to Notify.

Licensee shall promptly notify Licensor upon becoming aware of any violation of any anti-corruption laws by Licensee or its Affiliate or those acting on Licensee’s behalf in connection with the matters that are the subject of this Agreement and the performance by Licensee of its obligations hereunder.

(h) Compliance Audits.

Licensee shall maintain books and records that are complete and accurate in all material respects relating to its compliance by Licensee and its Affiliates that is engaged in carrying out activities in connection with this Agreement with anti-corruption laws and with respect to its obligations under this Agreement (collectively, the “Compliance Records”) for a period of two (2) years after the period to which such records relate or such longer period as required by Applicable Laws, which Compliance Records shall include: (a) its policies and procedures including those of Licensee and its Affiliates concerning compliance with anti-corruption laws with respect to its obligations under this Agreement, (b) records of any investigations and remedial and disciplinary actions undertaken to address material violations of anti-corruption laws with respect to its obligations under this Agreement and (c) records of any payments made by it or Licensee and its Affiliates in connection with this Agreement. Upon reasonable advance written notice to Licensee, Licensor shall be entitled, at its cost and expense, to have access to and audit the Compliance Records of Licensee and any of its Affiliates (to the extent such Compliance Records are not subject to attorney-client privilege) for a period of two (2) years after the period to which such records relate or such longer period as required by applicable anti-corruption laws. Licensor may not exercise this audit right more frequently than once during any twelve (12)-month period; provided, however, that if any audit by Licensor under this Section 4.2(h) reveals that Licensee or any of its Affiliates is or was not in material compliance with applicable anti-corruption laws in relation to the performance of its obligations under this Agreement, Licensor shall have the right to conduct such additional audits (for clarity, such additional audits shall apply only to the applicable Licensee and its Affiliates which was so determined during the initial audit in such twelve (12)-month period to not be in material compliance) during such twelve (12)-month period as may be reasonably required to determine whether Sub-Licensee and its Affiliates have appropriately remedied such non-compliance.

4.3. Termination for Non-Compliance.

Any uncured violation by Licensee or any of its Affiliates of any applicable anti-corruption laws in connection with its obligations under this Agreement shall be a material breach of this Agreement entitling Sub-Licensor to terminate this Agreement pursuant to Section 11.2(c).

4.4. Responsibility for Compliance.

Licensee acknowledges and agrees that neither Licensor, nor or any of its Affiliates or Licensor’s or its Affiliates’ officers, directors, employees, agents and representatives is authorized to waive compliance with the provisions of Section 4.3 and/or to give any direction, either written or oral, relating to the making of any commitment by Licensee or its agents to any Third Party in violation of the terms of this ARTICLE 4, and that Sub-Licensee shall be solely responsible for its compliance with all applicable anti-corruption laws irrespective of any act or omission of Merck or any of Merck’s Affiliates or Merck’s or its Affiliates’ officers, directors, employees, agents and representatives.

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 등 국문계약서에서 공정의무, 반부패의무, 비위행위금지, An

Tags : anticorruption, compliance, FCPA, 계약위반, 공정거래법, 공정의무, 국제계약, 기술이전, 라이선스, 반부패조항, 영문계약

작성일시 : 2019.06.05 12:00
Trackback 0 : Comment 0

기술이전, 라이선스, 특허실시, 공동연구개발 등 국문계약서에서 공정의무, 반부패의무, 비위행위금지, Anti-Corruption, Compliance 관련 계약조항 샘플

제 1 조 (공정의무)

1) 양 당사자(그 임직원을 포함)는 본 계약의 체결, 이행 및 유지에 있어 거래의 공정성에 대한 확보가 중요한 전제 조건임을 인식하고, 타방 당사자(그와 동일시 할 수 있는 친인척 등 관계자 포함) 또는 본 계약과 관련한 제3자(이하 “거래 상대방”이라 한다)에 대하여 거래의 공정성을 해할 수 있는 행위(이하 "비위행위”라 한다)를 하여서는 아니 된다. "비위행위"의 예는 다음 각 호에 열거되어 있는 바와 같으며, 이에 한하지 아니한다.

① 금전을 제공하는 행위

② 사회통념수준을 초과하는 선물 또는 식사를 제공하는 행위

③ 불건전 업소, 오락, 골프, 스키 등의 향응 및 접대를 하는 행위

④ 출장지원, 개인 휴가 지원, 사무실 비품 제공, 협찬/찬조 등의 편의를 제공하는 행위

⑤ 차용/매입/매도, 부채상환, 보증, 금전대차 등 금전 또는 부동산 관련 모든 거래행위

⑥ 공동투자 및 공동재산의 취득 기회를 제공하거나, 합작투자 또는 “거래 상대방”의 회사에 겸직하도록 하는 행위

⑦ “거래 상대방”의 주식이나 기타 관련업체의 주식을 제공 또는 투자하도록 하거나 기타 재산을 공동 투자 또는 취득하도록 하는 행위

⑧ 고용보장, 취업알선의 약속 등 미래에 대한 보장을 하는 행위

⑨ 기타 타방 당사자의 정도경영 준수사항을 위반하거나, “거래 상대방”이 공정하게 업무를 수행하는 데 지장을 초래하는 행위

2) 양 당사자는 거래 공정성 확보를 위해 다음 각 호의 사항을 협조하도록 한다.

① 타방 당사자의 임직원을 상대로 일방 당사자의 임직원 등에 의해 이루어진 “비위행위”가 발견되거나 “비위행위”에 대한 의혹이 있는 경우, 양 당사자는 그와 관련된 자료의 제출 또는 열람을 상대방 당사자에게 요구할 수 있으며, 이 경우 양 당사자는 해당 요구에 적극 협조하여야 한다.

② 일방 당사자는 타방 당사자의 임직원으로부터 본 조 제1항 각 호의 행위를 제의받거나, 이러한 사실을 인지한 때에는 타방 당사자의 관련 부서에 즉각 신고토록 한다.

③ 양 당사자는 본 계약 외에 상대 당사자의 정도경영 실천에 적극 협조한다.

3) 본 조는 본 계약의 종료(만료, 해지 또는 해제 포함) 후에도 유효하다.

4) 본 계약의 일방 당사자가 본 조항의 공정의무를 위반한 경우 그 상대방은 본 계약을 즉시 해지할 수 있다.

KASAN_국제계약, 영문계약에서 Anti-Corruption, Compliance 쟁점, 미국법 FCPA 관련 주

Tags : anticorruption, compliance, FCPA, 계약위반, 공정거래법, 공정의무, 국제계약, 기술이전, 라이선스, 반부패조항, 영문계약

작성일시 : 2019.06.05 11:00
Trackback 0 : Comment 0

국제계약, 영문계약에서 Anti-Corruption, Compliance 쟁점, 미국법 FCPA 관련 주요내용, 최근 제재사례 및 실무적 포인트 몇 가지

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMIN

Tags : anticorruption, compliance, FCPA, 계약위반, 공정거래법, 공정의무, 국제계약, 기술이전, 라이선스, 반부패조항, 영문계약

작성일시 : 2019.06.05 09:16
Trackback 0 : Comment 0

국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMINATION 영문조항 샘플

17. TERM AND TERMINATION.

17.1 Termination Prior to the Closing Date.

This Agreement may be terminated at any time prior to the Closing Date (with respect to Sections 17.1(b) and 17.1(c) below, by written notice by the terminating Party to the other Party): (a) by mutual written agreement of the Parties;

(b) by Licensor or Licensee, if a court of competent jurisdiction or other Governmental Authority shall have issued a non-appealable final order, decree or ruling or taken any other non-appealable final action, in each case, having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement; provided, however, that the right to terminate this Agreement under this Section 17.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the primary cause of, or materially contributed to, such action; or

(c) by Licensee, if Licensor has breached any representation, warranty, covenant or agreement of Licensor set forth in this Agreement which (i) would result in a failure of a condition set forth in Section 13.2 and (ii) is not cured within thirty (30) calendar days after written notice thereof.

17.2 Term.

Except as provided in Section 17.1, this Agreement shall continue until the date of expiration of the Royalty Term, unless earlier terminated in accordance with this Article 17 (the “Term”).

17.3 Termination of the Agreement After the Closing Date.

(a) Termination by Licensee.

Licensee may terminate this Agreement in its entirety or in part (including, for example, on a country-by-country basis) for any reason (a) upon at least ninety (90) days prior written notice to Licensor if such notice is delivered prior to the First Commercial Sale of a Licensed Product anywhere in the Territory or (b) upon at least one hundred eighty (180) days prior written notice to Licensor if such notice is delivered after the First Commercial Sale of a Licensed Product anywhere in the Territory. In the event of any significant adverse clinical events or the termination of a Clinical Trial for safety reasons and Licensee terminates this Agreement under this Section 17.3(a), the foregoing notice periods in clauses (a) and (b) shall be reduced to forty-five (45) days and ninety (90) days, respectively.

(b) Termination for Material Breach.

If either Party believes the other is in material breach of its obligations under this Agreement, it may give notice of such breach to the other Party, which Party shall have sixty (60) days in which to remedy such breach, or thirty (30) days in the case of material breach of any payment obligation hereunder.

Such sixty (60) day period shall be extended in the case of a breach not capable of being remedied in such sixty (60) day period so long as the breaching Party uses diligent efforts to remedy such breach and is pursuing a course of action that, if successful, will effect such a remedy; provided, however, that such cure period shall not be extended more than sixty (60) additional days.

If such alleged breach is not remedied or is not capable of being remedied within the period set forth above, the non-breaching Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement upon written notice to the other Party. In the event of a dispute regarding any payments due and owing hereunder, all undisputed amounts shall be paid when due and the balance, if any, shall be paid promptly after settlement of the dispute including any accrued interest thereon.

(c) Consequences of Termination.

In the event that either Party terminates this Agreement, then as of the effective date of such termination, the following terms and conditions shall apply:

(i) Termination by Licensor for Licensee’s Material Breach.

In the event of termination of this Agreement by Licensor pursuant to Section 17.3(b) for Licensee’s uncured material breach, and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:

(A) all licenses and rights granted by either Party under this Agreement shall terminate with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c) which shall become perpetual, worldwide and fully paid;

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination;

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination;

(D) Licensee shall transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory.

(ii) Termination by Licensee.

Subject to Section 17.3(c)(ii)(E), in the event of termination of this Agreement by Licensee pursuant to Section 17.3(a), and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:

(A) all licenses and rights granted by either Party under this Agreement shall terminate, with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c), which shall become worldwide, subject to Licensor’s obligations under subsection (E) below;

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination;

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination;

(D) Licensee shall, upon receipt of reasonable consideration from Licensor based on an actual cost basis, transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory; and

(E) in partial consideration for (A) Licensee’s costs of obtaining and maintaining such Regulatory Approvals and Commercializing Licensed Products in the Territory prior to the date of such termination, and/or (B) subject to Section 19.1, the license granted under the Licensee Inventions, Licensor shall pay to Licensee following the effective date of such termination, on a product-by-product and country-by-country basis, a commercially reasonable royalty to be negotiated in good faith by the Parties, on all sales by Licensor, its Affiliates and Sublicensees, of products that would have been Licensed Products, had they been sold by Licensee prior to the effective date of such termination.

(iii) Termination by Licensee for Licensor’s Material Breach.

In the event that Licensee has the right to terminate this Agreement for Licensor’s uncured material breach pursuant to Section 17.3(b), Licensee may terminate this Agreement or, in lieu of such termination, by written notice to Licensor after a determination that such breach was a material breach and was not cured before the expiration of the cure period set forth in Section 17.3(b), elect to retain all of the rights and licenses granted to Licensee hereunder for the remainder of the Term. Following such an election by Licensee:

(A) Licensee may request that damages be awarded to Licensee for Licensor’s uncured material breach by final and binding arbitration conducted in accordance with Section 19.12. In determining whether damages should be awarded to Licensee, the arbitrators shall consider the nature of Licensor’s uncured material breach and the impact of such uncured material breach on Licensee and the transactions contemplated by this Agreement.

In the event that such final and binding arbitration determines that Licensee should be awarded damages, Licensee shall be entitled to deduct the amount of such damages from milestone and royalty payments to be paid to Licensor under Sections 8.2 and 8.3;

(B) the limitations applicable to Licensor’s activities as set forth in Sections 2.3(a) and 2.4 shall continue to apply; and

(C) the license granted by Licensee to Licensor under Section 9.2(c) shall terminate.

17.4 Surviving Obligations.

Upon termination of this Agreement, the Parties shall remain obligated to make all payments which have accrued under this Agreement prior to the date of termination, when and as they become due and payable. In addition, the provisions in Articles 1, 9, 10, 14, 15, 16, 18 and 19, and Sections 2.6, 5.2, 5.7, 7.6, 8.3(h), 8.7 (with respect to payment accruing prior to the effective date of termination), 8.8, 8.9, 17.3(c), 17.4 and 17.5 of this Agreement shall survive termination of this Agreement for any reason.

17.5 Accrued Rights.

Termination or expiration of this Agreement shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. Termination by a Party shall not be an exclusive remedy and all other remedies will be available to the terminating Party, in equity and at law.

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASS

Tags : Termination, 계약위반, 계약조항샘플, 계약종료, 계약해지, 국제계약, 기술이전, 라이선스, 영문계약, 특허실시

작성일시 : 2019.06.04 13:00
Trackback 0 : Comment 0

국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASSISTANCE 조항 샘플

ARTICLE 2 - TECHNICAL ASSISTANCE

2.1 TECHNICAL DOCUMENTATION

(a) Licensor shall furnish to Licensee, in accordance with the time schedule to be agreed upon between the Parties, one (1) set of hard copies of the Technical Documentation. If Licensee discovers that any of the documents are missing or illegible or damaged, Licensee shall inform Licensor in writing and Licensor shall make such documents available for Licensee within twenty (20) days of receiving such notice.

(b) The foregoing Technical Documentation to be furnished under paragraph 2.1 (a) above shall be delivered to Licensee and shall be the latest version as of the time it is delivered or sent.

(c) Licensee shall pay Licensor for any additional copies of the Technical Documentation requested by Licensee at the rates agreed upon in writing by both Parties prior to sending.

(d) Nothing in this Agreement shall be construed to require that Licensor furnish Licensee with any technical information on any products other than Licensed Product or any technical information which may not be furnished because of a government contract, act, regulation or restriction or the proprietary interest of a third party.

(e) Errors in Technical Documentation. Each Party shall promptly advise the other of any significant error it may discover in the Technical Documentation. In that event, Licensor shall correct any error in the Technical Documentation and shall furnish such corrected Technical Documentation to Licensee without charge.

(f) Strict Compliance with Technical Documentation. In order to maintain the quality of the Licensed Products manufactured and assembled by Licensee pursuant to this Agreement, Licensee shall manufacture and/or assemble the Licensed Products in strict accordance with the standards and specifications stated in the Technical Documentation provided by Licensor and as otherwise specified by Licensor. Licensee shall exercise the utmost care in the selection of the materials and parts to be used and incorporated into the Licensed Products.

2.2 ASSISTANCE BY LICENSOR

Licensor shall provide reasonable assistance in the use of the Technical Documentation to the extent such assistance is reasonably necessary for Licensee to make use of the Technical Documentation to manufacture the Licensed Product. Such assistance may include, but will not be limited to, technical assistance, training, testing and limited application engineering services.

- 라이센서의 조력의무를 선언적으로 규정한 조항임. 제조에 필요한 기술정보 활용을 가능케 하도록 조력의무를 규정하고 있어 상당히 포괄적임.

- 이하에서 구제적인 비용을 규정할 경우 라이센서의 수입원이 되지만, 그렇지 않을 경우 부담조항이 될 수 있음.

2.3 TECHNICAL ASSISTANCE

(a) At the request of Licensee, Licensor shall, at times agreed upon by the Parties, dispatch its engineers to Licensee to provide technical assistance on matters concerning the use of the Technical Documentation during the Technical Cooperation Period. All costs and expenses of such Licensor's personnel dispatched to Licensee shall be borne, or reimbursed to Licensor, by Licensee and shall include:

(i) round trip economic air fare between Korea and China;

(ii) suitable accommodations, meals, traveling and transportation expenses in China and other reasonable charges in connection with the performance of their duties hereunder;

(iii) wage and daily allowance, payable to Licensor, on its demand, amounting to U$500 per Man Day for Licensor's personnel;

(b) Licensee shall take appropriate steps necessary to protect and ensure the safety of Licensor's personnel and their property, including without limitation, against war, war-like operation, terror, revolution, civil commotion, catastrophe and acts of public enemies. Licensor reserves the right to instruct any or all of its dispatched personnel to return to Korea, or such other place as it may designate, at Licensee's expense when, in Licensor's sole judgment , one of the above-mentioned situations arises which may endanger the safety and well-being of such personnel.

- 기술자 파견에 따른 안전보장은 실시자 부담임

(c) Licensee is responsible for obtaining any permits or authorizations required for Licensor's personnel to enter China to provide services hereunder, and to bring any related materials required by Licensor.

- 기술자 파견에 따른 출입국 보장은 실시자 부담

(d) The number of such personnel, the period of their stay at Licensee's plant and other terms and conditions not set forth herein shall be agreed upon between the Parties on a case by case basis.

2.4 TRAINING

At the request of Licensee, Licensor will, during the Technical Cooperation Period, provide training on the use of the Technical Documentation for Licensee's employees (the "Trainees") at Licensor's place or other places designated by Licensor, subject to the following terms and conditions:

(i) Licensor and Licensee shall agree on the most efficient training program for the Trainees;

(ii) Licensee shall bear all the cost and expenses relating to the Trainees, including but not limited to their salaries, round trip airfare between China and Korea, lodgings and meals of Trainees in Korea, transportation and insurance;

(iii) Licensor shall provide working lunches for the trainees during working days and transportation for the trainees between dormitory and training site.

(iv) Licensee shall pay to Licensor as training fee, payable upon demand, US$300 per Trainee per day, as the compensation of training services provided by Licensor;

(v) Licensee shall instruct the Trainees to observe and abide by all rules and regulations of Licensor and the laws of Korea during their training period;

(vi) All Trainees shall be insured at the expense of Licensee by an internationally recognized accident compensation insurance during the entire training period between their departure from and return to China;

(vii) Licensee shall indemnify and hold harmless Licensor against any loss, damage, claim, liabilities, cost or expense arising out of any act of a Trainee or any injury or death of the Trainee or any damage to his/her property.

2.5 SUPPORT OF TESTS

Pursuant to the terms of a purchase order, sale agreement or other document to be separately agreed by the Parties or Licensee and Delphi, Licensor will support the necessary manufacturing Part Production Approval Process validation tests for the Licensed Products.

2.6 SAMPLE TEST AND VERIFICATION

Before distribution and sale of any of the Licensed Product manufactured or assembled hereunder, Licensee shall submit, at its expense, samples of the Licensed Product for approval by Licensor. Licensor shall promptly conduct appropriate tests on such samples and advise Licensee of the results thereof. The costs of any tests on the samples shall be responsibility of Licensee, and Licensor shall advise Licensee of the test fees in advance.

KASAN_특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATI

Tags : 계약위반, 계약조항샘플, 국제계약, 기술이전, 기술자료제공, 기술지도, 기술지원, 라이선스, 영문계약, 특허실시

작성일시 : 2019.06.04 08:47
Trackback 0 : Comment 0

특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTIES 샘플

11. REPRESENTATIONS AND WARRANTIES.

11.1 The Parties ’Representations and Warranties.

Each Party hereby represents, warrants and covenants to the other Party, as of the Effective Date (or as of the Closing Date in the case of Section 11.1(h)), that:

(a) such Party (i) is a corporation duly organized and validly existing under the laws of its jurisdiction of organization, and (ii) has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement;

(b) such Party has sufficient legal and/or beneficial title under its intellectual property rights necessary for the purposes contemplated under this Agreement and to grant the licenses contained in this Agreement;

(c) such Party is not aware of any pending or threatened litigation, nor has it received any notice of claim, alleging that it has violated or would violate, through the manufacture, import and/or sale of Licensed Products hereunder, or by conducting its obligations as currently proposed under this Agreement, any intellectual property or other rights of any Third Party;

(d) to such Party’s knowledge, all of its employees, officers, independent contractors, consultants and agents have executed agreements requiring assignment to such Party of all inventions made during the course of and as a result of their association with such Party and obligating the individual to maintain as confidential the Confidential Information of such Party;

(e) such Party has the power, authority and legal right, and is free to enter into this Agreement and, in so doing, will not violate any other agreement to which such Party is a party as of the Effective Date and such Party has maintained and will maintain and keep in full force and effect all agreements and regulatory filings necessary to perform its obligations under the Agreement and, during the Term, such Party shall not enter into any agreement with a Third Party that will conflict with the rights granted to the other Party under this Agreement;

(f) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity;

(g) such Party has taken all corporate action necessary to authorize the execution, delivery and performance of this Agreement;

(h) such Party has obtained all consents, approvals and authorizations of all Regulatory Authorities and other Third Parties reasonably deemed necessary by such Party to be obtained in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder;

(i) the execution and delivery of this Agreement and the performance of such Party’s obligations hereunder: (i) do not conflict with or violate any provision of the certificate of incorporation, bylaws, limited partnership agreement or any similar instrument of such Party, as applicable, in any material way; (ii) to such Party’s knowledge, do not conflict with, violate or breach or constitute a default or require any consent under any indenture, mortgage, contract or instrument to which it is party or by which it is bound; and (iii) to such Party’s knowledge, do not conflict with, violate, or breach or constitute a default or require any consent under, any requirement of Applicable Laws or court or administrative order by which such Party is bound;

(j) except in connection with or related to the settlement between Licensee A and the United States Department of Justice, announced on September 1, 2010, neither such Party, nor any of such Party’s employees, officers, independent contractors, consultants or agents who will render services relating to Licensed Products: (i) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a; or (ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a. If during the Term a Party has reason to believe that it or any of its employees, officers, independent contractors, consultants or agents rendering services relating to Licensed Products: (x) is or will be debarred or convicted of a crime under 21 U.S.C. Section 335a; or (y) is or will be under indictment under said Section 335a, then such Party shall immediately notify the other Party of same in writing; and

(k) such Party currently has no research or development project, or agreement with any Third Party, that, in such Party’s reasonable scientific or business judgement, (i) requires or is likely to require changes to the Development Plan attached hereto as Exhibit 4.1, or (ii) is likely to interfere with such Party’s ability to enter into and perform its obligations under this Agreement.

11.2 Representations and Warranties of Licensor M.

Licensor M hereby represents, and warrants and covenants to Licensee A, as of the Effective Date, that:

(a) Licensor M is the sole and exclusive owner of all right, title and interest, in, to and under the Licensed Intellectual Property in the Territory;

(b) M is the sole and exclusive owner of all right, title and interest, in, to under the Licensed Intellectual Property necessary or useful in the Manufacture of Licensed Products;

(c) M has sufficient rights to grant the rights and licenses granted herein, free and clear of any security interests, claims, encumbrances or charges of any kind that would conflict in any material respect with the rights and licenses granted hereunder;

(d) M has not assigned or granted to any Third Party any rights under the Licensed Intellectual Property that cover Licensed Products in the Territory except as granted to independent contractors in the ordinary course of business in connection with M's research, Development and Manufacturing of Licensed Products, and consistent with the terms and intent of this Agreement;

(e) (i) M has not received any written notice from any Third Party asserting or alleging that any Development, Manufacturing, or Commercialization of the Licensed Products has infringed or misappropriated any Patent or intellectual property right of such Third Party, (ii) to the knowledge of M, the manufacture, use, offer for sale, sale or importation of Licensed Products in the Territory has not infringed and, as of the Effective Date, will not infringe, any Patent of any Third Party or misappropriate any technology of any Third Party, and (iii) there are no pending, and, to the knowledge of M, no threatened, adverse actions, suits, arbitrations, litigations, or proceedings of any nature, civil, criminal, regulatory or otherwise, in law or in equity, against M or any of its Affiliates alleging that the Development, Manufacture, Commercialization or other exploitation of Licensed Products has infringed any Patent, or misappropriated any intellectual property right of any Third Party;

(f) to Licensor M’s knowledge, the issued Patents within the M Patent Rights in the Territory are valid and enforceable;

(g) all applicable maintenance and renewal fees with respect to the M Patent Rights in the Territory have been paid and all documents, and certificates required to be filed for the purpose of maintaining such M Patent Rights have been filed;

(h) to Licensor M’s knowledge, no Third Party has asserted that any Licensed Intellectual Property is invalid or not enforceable;

(i) (i) other than as disclosed by M in writing to A prior to the Effective Date, none of the M Patent Rights, were developed with federal or state funding from any Governmental Authority, (ii) no Governmental Authority has any march in rights or other rights to use the Licensed Intellectual Property in the Territory, and (iii) neither the execution and delivery of this Agreement nor the performance hereof by M will result in the breach of, or give rise to, any right of termination, rescission, renegotiation or acceleration under, or trigger any other rights under, any agreement or contract to which M is a party, or to which it may be subject, that relates to the Licensed Products;

(j) no written communication has been received by M from any Third Party that alleges, and there is no pending litigation that alleges, that (i) any issued M Patent is invalid or unenforceable as of the Effective Date, or (ii) any patent application included in the M Patents, if issued, would be, invalid or unenforceable;

(k) to the knowledge of Licensor M, no Third Party (i) is infringing any M Patent Rights or has misappropriated any M Know-How, or (ii) has challenged the ownership, scope, duration, validity, enforceability, priority or right to use any M Patent Rights (including, by way of example, through the institution of or written threat of institution of interference, re-examination, review, supplemental examination, derivation proceeding, protest, opposition, nullity or similar invalidity proceeding before the U.S. Patent and Trademark Office or any analogous foreign entity) or any M Know-How;

(l) the Licensed Intellectual Property licensed to Licensee A hereunder constitutes all of the intellectual property rights Controlled by M that are necessary for A to Commercialize Licensed Products in the Territory;

(m) to Licensor M’s knowledge, M has complied in all material respects with all Applicable Laws in the prosecution and maintenance of the M Patent Rights in the Territory;

(n) all of Licensor M’s and its Affiliates’ employees, officers, and consultants/contractors involved in the research, Manufacture or Development of Licensed Products are and have been obligated to assign to M or such Affiliate, as the case may be, all Inventions claimed in the M Patent Rights and to maintain as confidential the Confidential Information of M or such Affiliate, as applicable; and

(o) all inventors of any Inventions included within the M Patent Rights and M Know-How have assigned their entire right, title, and interest in and to such Inventions and the corresponding Patents and Information to M and have been listed in the M Patent Rights as inventors.

KASAN_특허실시, 기술이전, 라이선스 계약서에서 개량발명, 특허출원, 등록 및 유지, 공유쟁점, 특허침해소송,

Tags : 계약실무, 국제계약, 기술이전, 라이선스, 영문계약, 영업비밀, 조항샘플, 진술보증, 특허실시

작성일시 : 2019.05.31 16:00
Trackback 0 : Comment 0

특허실시, 기술이전, 라이선스 계약서에서 개량발명, 특허출원, 등록 및 유지, 공유쟁점, 특허침해소송, 무효도전불가 포함 영문계약 조항 샘플

9. INVENTIONS, KNOW-HOW AND PATENTS.

9.1 Existing Intellectual Property.

ALL EXISTING INTELLECTUAL PROPERTY OF EITHER PARTY, INCLUDING ALL PATENTS, INFORMATION, AND OTHER INTELLECTUAL PROPERTY OWNED BY SUCH PARTY AS OF THEEFFECTIVE DATE, SHALL REMAIN THE SOLE PROPERTY OF SUCH PARTY, SUBJECT TO THE RIGHTS AND LICENSES GRANTED TO THE OTHER PARTY UNDER SUCH INTELLECTUAL PROPERTY EXPRESSLY PROVIDED IN THIS AGREEMENT. OTHER THAN AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY GRANTS ANY RIGHT, TITLE, OR INTEREST IN ANY PATENT, INFORMATION, OR OTHER INTELLECTUAL PROPERTY RIGHT CONTROLLED BY SUCH PARTY TO THE OTHER PARTY.

9.2 Ownership of Inventions.

(a) Ownership of inventions, developments or discoveries, in each case, with respect to Licensed Products, whether patentable or non-patentable, invented or otherwise discovered or generated during the Term in the course of performing each Party’s obligations under this Agreement and the Development Plan (“Inventions”), and any and all intellectual property rights therein, shall be determined in accordance with the rules of inventorship in accordance with United States patent law.

For clarity, (i) Licensor M shall solely own any Inventions and intellectual property rights therein that are made, conceived, reduced to practice, authored, or otherwise discovered solely by M or any of its employees, Affiliates, licensees, sublicensees (where permitted), independent contractors, or agents including, without limitation, any Patent in which all of the claims included in such Patent claim only such solely owned Invention (the “M Inventions”), (ii) Licensee A shall solely own any Inventions and intellectual property rights therein that are made, conceived, reduced to practice, authored, or otherwise discovered solely by A or any of its employees, Affiliates, licensees, sublicensees (where permitted), independent contractors, or agents including, without limitation, any Patent in which all of the claims included in such Patent claim only such solely owned Invention (the “A Inventions”), and (iii) the Parties shall jointly own any Inventions and intellectual property rights therein that are made, conceived, reduced to practice, authored, or otherwise discovered jointly by the Parties or any of their employees, Affiliates, licensees, sublicensees (where permitted), independent contractors, or agents including, without limitation, any Patent on such jointly owned Invention (each, a “Joint Invention”).

Subject, in all cases, to the applicable terms and conditions of this Agreement, each Party shall have the right to use and license such Joint Inventions and all intellectual property rights therein for any and all purposes without the need to account to or seek permission from the other Party; provided, however, that neither Party shall assign or transfer any such Joint Invention to a Third Party without the prior written consent of the other Party. For clarity, the foregoing shall not be construed as granting or conveying to either Party any license or other rights to the other Party’s other intellectual property rights, unless otherwise expressly set forth in this Agreement.

(b) Notwithstanding the foregoing, if any Patent from an A Invention claims priority to one or more Patents included in the M Patent Rights, and/or A reasonably believes that the claims of any Patent filed with respect to such A Invention would be anticipated by such M Patent Right in such a way as to prevent a Patent from issuing from such A Invention, A may, at its sole discretion, assign to M without additional consideration all of its right, title and interest in and to an A Invention (thereafter an “Assigned Invention”), and (i) all Assigned Inventions shall thereafter be added to the M Patent Rights and shall be subject to the licenses granted under this Agreement; provided that the license to such Assigned Inventions shall be non-royalty-bearing, and such Assigned Inventions shall not be included in any determination of the existence of Valid Claims for the purposes of determining the Royalty Term hereunder, and (ii) M hereby covenants and agrees that it shall not assert, at any time during the Term or thereafter, such Assigned Inventions against A (including its present and future Affiliates, successors, assigns, licensees, distributors, contractors, agents, and customers.

(c) Subject to the terms and conditions of this Agreement, during the Term, A hereby grants to M a non-exclusive, fully sublicenseable, transferable license under the A Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property (i) to make, have made, develop, use, sell, offer for sale and import Licensed Products outside the Territory, and (ii) to make and have made Licensed Products inside the Territory for or on behalf of A in accordance with the terms of the Supply Agreement. In the event of termination of this Agreement by A pursuant to Section 17.3(a), the license granted in this Section 9.2(c) shall become worldwide, subject to Section 17.3(c)(ii)(E). In the event of termination of this Agreement by M pursuant to Section 17.3(b), the license granted in this Section 9.2(c) shall become perpetual, worldwide and fully-paid.

9.3 Patent Prosecution and Maintenance.

(a) Subject to the terms of Sections 9.1, 9.2, 9.3(a) and 9.3(c), A shall have the sole right, in its reasonable discretion, to prepare, file, prosecute, conduct and control interferences, re-examinations, and post-issuance proceedings (including without limitation, post-grant review, inter parties review, derivation proceedings and supplemental examination before the United States Patent and Trademark Office and the relevant local equivalent thereof; and applications for patent term extensions, supplementary protection certificates, or equivalents thereof), maintain, and enforce any Patents in the Territory related to the Licensed Products or included in M Patent Rights at A’s expense, in full compliance with all applicable laws, regulations, and duties. A shall keep M timely apprised of all significant events concerning the filing, prosecution and maintenance of any Patents in the Territory related to the Licensed Products or included in M Patent Rights (including, without limitation, preparation of patent applications, filing of patent applications, office actions, responses to office actions, requests for reexamination, interference proceedings, term adjustments, requests for term extensions, and abandonment or discontinuation decisions), and shall consider and incorporate all reasonable input from M regarding such preparation, filing, prosecution and maintenance. In the event that A elects not to prosecute and/or maintain any Patent included in the M Patent Rights in the Territory, it shall notify M of such election not to prosecute and maintain such M Patent Rights not less than thirty (30) days prior to any patent office deadline, and M shall have the right, but not the obligation, to elect, upon written notification to), to perform such activities, at M’s expense (such rights, the “Abandoned Patent Rights”, provided that if M elects to take over the prosecution and maintenance of such Abandoned Patent Rights, A shall assign to M without additional consideration all of its right, title and interest in and to such Abandoned Patent Rights, and cooperate with and take reasonable additional actions and execute such agreements, instruments, and documents as may be reasonably required to perfect right, title and interest in, to and under such Abandoned Patent Rights. Following such assignment, such Abandoned Patent Rights shall no longer be included within the scope of the M Patent Rights, or subject to the licenses granted hereunder.

(b) Subject to the terms of this Section 9.3(b) and Section 9.3(c), M shall have the sole right, in its sole discretion, to prepare, file, prosecute, conduct and control interferences, re-examinations, and post-issuance proceedings (including without limitation, post-grant review, inter parties review, derivation proceedings and supplemental examination before the Korean Intellectual Property Office; and applications for patent term extensions, supplementary protection certificates, or equivalents thereof), maintain, and enforce any Patents outside the Territory related to the Licensed Products or included in MEDYTOX Patent Rights at M’s expense, in full compliance with all applicable laws, regulations, and duties. M shall keep A timely apprised of all significant events concerning the prosecution and maintenance of any Patents outside the Territory related to the Licensed Products or included in M Patent Rights (including, without limitation, preparation of patent applications, filing of patent applications, office actions, responses to office actions, requests for re-examination, interference proceedings, term adjustments, requests for term extensions, and abandonment or discontinuation decisions), and shall reasonably consider and incorporate, in good faith, all reasonable input from A regarding such preparation, filing, prosecution and maintenance.

(c) Each Party shall provide the other Party all reasonable assistance and cooperation, at the other Party’s request and expense, in the patent prosecution efforts provided above in this Section 9.3 and in Section 9.4, including providing any necessary Information, and powers of attorney, and executing and delivering any other required documents or instruments for such patent prosecution. Each Party shall execute and deliver to the other assignments with respect to any Joint Inventions, A Inventions, and M Inventions, as applicable, in a mutually agreeable form and will take whatever actions reasonably necessary (including the appointment of the other Party as its attorney in fact solely to make such assignment) to effect such assignment. The prosecuting Party under this Section 9.3 agrees to conduct such prosecution toward the objective of optimizing overall patent protection for Licensed Products.

(d) Within thirty (30) days after the Closing Date, M shall deliver to A copies of all patent prosecution files relating to the M Patent Rights in the Territory.

9.4 Joint Patents.

(a) Subject to this Section 9.4(a), A shall prepare, file, prosecute and maintain Patents derived from Joint Inventions (“Joint Patents”) in the Territory in the names of M and A as co-owners, and shall bear its own internal costs thereof, and the external costs for such prosecution (e.g., outside counsel, filing fees, etc.). A shall keep M timely apprised of all significant events concerning the prosecution and maintenance of any Joint Patents in the Territory (including, without limitation, preparation of patent applications, filing of patent applications, office actions, responses to office actions, requests for re-examination, interference proceedings, term adjustments, requests for term extensions, and abandonment or discontinuation decisions), and shall reasonably consider and incorporate, in good faith, all reasonable input from M regarding such preparation, filing, prosecution and maintenance. In any event, A will not finally abandon, disclaim, or dedicate to the public any claims or limit any claims specific to Licensed Products in the Territory without M’s prior written consent.

(b) Subject to this Section 9.4(b), M shall prepare, file, prosecute and maintain Joint Patents outside the Territory in the names of M and A as co-owners, and shall bear its own internal costs thereof, and the external costs for such prosecution (e.g., outside counsel, filing fees, etc.). M shall keep A timely apprised of all significant events concerning the prosecution and maintenance of any Joint Patents outside the Territory (including, without limitation, preparation of patent applications, filing of patent applications, office actions, responses to office actions, requests for reexamination, interference proceedings, term adjustments, requests for term extensions, and abandonment or discontinuation decisions), and shall reasonably consider and incorporate, in good faith, all reasonable input from A regarding such preparation, filing, prosecution and maintenance. In any event, M will not finally abandon, disclaim, or dedicate to the public any claims or limit any claims specific to Licensed Products outside the Territory without A’s prior written consent

9.5 Third Party Infringement Claims.

(a) Notice. If the Development, Manufacture, import, use, Commercialization or sale of a Licensed Product in the Territory results in a claim by a Third Party alleging infringement of a Patent owned or controlled by such Third Party (“Third Party Claim”), the Party first having notice of such claim shall promptly notify the other Party in writing. The notice shall set forth the facts of the Third Party Claim in reasonable detail, and the Parties shall agree on and enter into a “common interest agreement” wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action.

(b) Defense. Subject to M’s indemnification obligations under Section 15.2(d), A shall have control over the handling and be responsible for defending any Third Party Claim in the Territory including, without limitation, the selection of counsel and settlement, but shall consult with M regarding the strategy for such defense and keep M apprised of the status of, and substantive developments in, the case. In the event that M is named as a defendant in such litigation, counsel representing A shall also represent M to the extent permitted under Applicable Laws at A’s cost and expense. In the event that M retains separate counsel for such defense, all reasonable costs and expenses of such separate counsel shall be borne by M. If A recovers monetary damages in such claim, suit or action, such recovery shall first be allocated to the reimbursement of any expenses incurred by A in such litigation (including, for this purpose, a reasonable allocation of expenses of internal counsel). If after such reimbursement any funds remain from such damages or other sums recovered, such remaining funds shall be included in Net Sales subject to the royalty payment by A to M pursuant to Section 8.3.

9.6 Enforcement of M Patent Rights Against Third Parties.

(a) Each Party shall notify the other Party promptly of any conduct on the part of a Third Party that it reasonably believes may be a potential infringement of M Patent Rights in the Territory, including the facts of such alleged infringement in reasonable detail. The Parties shall thereafter reasonably cooperate to promptly determine whether and the extent of any such infringement.

(b) A shall have the first right, but not the obligation, to enforce M Patent Rights or Joint Patents against any such infringing activities in the Territory, at A’s expense. If A fails to initiate litigation or take steps to abate such infringement with respect to M Patent Rights within ninety (90) days of a written request by M to do so, M, in its discretion, may undertake such action as it deems necessary to enforce the M Patent Rights or Joint Patents in the Territory, at M’s expense.

(c) Each Party agrees to cooperate fully and provide each other with information or assistance that the other Party may reasonable request in connection with any litigation initiated pursuant to this Section 9.6, including voluntarily consenting to be named as a plaintiff in an action commenced by the other Party.

(d) The Party initiating the action under Section 9.6(b) shall have control over the handling of the litigation, including the selection of counsel and settlement; provided, however, that no Party shall settle any action in a manner that will substantively adversely affect the rights of the other Party (including without limitation the licenses granted herein) without the consent of such other Party, which consent shall not unreasonably be withheld and, further provided that such other Party shall have the right, at its expense (except in the case of a conflict), to be represented in such action by separate counsel of its own choice. The Party controlling such litigation shall keep the other Party reasonably informed about the status and developments in such action, including considering, in good faith, the input of the other Party regarding the strategy and handling of the litigation.

(e) If A initiates any action under Section 9.6(b), A shall be entitled to offset all reasonable outside counsel fees and expenses (including expert fees and expenses, but excluding the costs of non-conflicted, separate counsel of a Party) of any such action against the royalty payments due to M under Section 8.3.

All recoveries, lumpsum settlements, royalty payments or other consideration received by the Parties as a result of any such litigation or settlement of any infringement (directed by either Party) shall be deemed to be Net Sales for the purposes of calculating the royalties due under Section 8.3.

9.7 Regulatory Data Protection.

To the extent required by or permitted by Law, A will, at its reasonable discretion, decide whether to list with the applicable Regulatory Authorities during the Term any applicable M Patent Rights covering any Licensed Product that A intends to, or has begun to, Commercialize, and that has become the subject of an application for Regulatory Approval submitted to the FDA or any equivalent Regulatory Authority in any jurisdiction.

In the event A desires to include in such listing any M Patent Right, then the Parties shall discuss such request in good faith and M will not unreasonably withhold consent to such listing, and will provide A all reasonable assistance and cooperation, at A’s request and expense, in the listing efforts, including providing any necessary Information, and powers of attorney, and executing and delivering any other required documents or instruments for such listing; provided that it shall not be unreasonable for M to withhold its consent if such extension would materially adversely affect such M Patent Right.

Such listings may include all so called “Orange Book” listings required under the Hatch-Waxman Act or listing of Patents as provided in the patent dispute resolution procedures of the Biologics Price Competition and Innovation Act of 2009 or under 42 U.S.C. § 262(l) or similar provisions in the Territory during the Term. Prior to such decision on listings, the Parties will meet to evaluate and identify all applicable Patents to be listed and A shall reasonably incorporate and address suggestions provided by M as to the listing or non-listing of any applicable Patents.

9.9 No Challenge to Licensed Patent Rights. Licensee A shall not, during the Term, challenge or assist others to challenge the validity, scope, or enforceability of, or otherwise oppose, any Patent included in the Licensor M Patent Rights.

KASAN_특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실

Tags : 개량발명, 공동연구개발, 국제계약, 기술이전, 라이선스, 바이오신약, 영문계약, 특허실시, 특허유지관리, 특허조항

작성일시 : 2019.05.30 13:28
Trackback 0 : Comment 0

특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실무적 포인트 몇 가지

KASAN_대한상사중재원의 조정 (Mediation) 개요 설명 – 중재(Arbitration)와 엄격하게 구별.p

Tags : 공동연구개발, 국제계약, 기술이전, 라이선스, 분쟁해결조항, 실무적대응방안, 영문계약, 중재조항, 특허실시

작성일시 : 2019.05.29 16:01
Trackback 0 : Comment 0

대한상사중재원의 조정 (Mediation) 개요 설명 – 중재(Arbitration)와 엄격하게 구별

조정 정의

조정(Mediation)은 분쟁 당사자가 조정인의 도움을 받아 당사자 사이의 대화와 상호양해를 통하여 조리(條理)를 바탕으로 분쟁을 실정에 맞게 자율적으로 해결하는 제도입니다. 중립적인 제3자인 조정인이 분쟁 당사자간의 합의를 통해 분쟁을 해결하도록 도와주는 ADR 제도 중의 하나가 조정(調停)입니다.

분쟁을 조정에 의하여 해결하기로 하는 합의를 조정합의(調停合意)라고 합니다. 대한상사중재원의 조정을 이용하기 위해서는 분쟁 당사자간에 체결한 계약서나 합의서 등에 '대한상사중재원의 조정규칙에 의한 조정 또는 대한상사중재원의 조정에 따라 해결하기로 합의한 경우' 즉 조정합의가 있는 경우에 해당하여야 합니다.

조정합의는 사전 합의(조정 조항)나 사후 조정합의 형식으로 할 수 있습니다.

당사자간에 조정합의가 없는 경우나 사후 조정합의가 곤란한 경우 일방 당사자(신청인)는 중재원에 조정참여 권유요청을 할 수 있습니다. 이 경우 중재원은 타방 당사자(피신청인)에게 조정참여 권유요청을 하고, 피신청인이 동의하면 조정절차를 진행하게 됩니다.

조정인의 역할

조정인은 당사자들이 분쟁을 우호적으로 해결하도록 협조하여야 합니다. 조정인은 당사자간의 거래관행 및 분쟁과 관련된 제반 상황 등을 고려하여 공정하고 객관적이며, 형평과 선의 원칙에 따라 분쟁을 조정하여야 합니다. 조정인은 언제든지 구두 또는 서면으로 당사자들에게 조정안을 제시할 수 있습니다.

조정인의 의무

조정인은 조정에 관하여 공정성과 독립성을 유지하여야 합니다. 조정인은 그 자신의 공정성 또는 독립성에 관하여 정당한 의문을 야기시킬 수 있는 사유가 있을 때에는 지체없이 이를 사무국에 고지하여야 합니다. 사무국은 조정인으로부터 그러한 고지를 받으면 즉시 당사자들에게 통지합니다.

조정절차 개요

Tags : 계약분쟁, 국제계약, 기술이전, 대한상사중재원, 라이선스, 분쟁해결, 영문계약, 조정, 조정권유, 조정합의

작성일시 : 2019.05.29 09:00
Trackback 0 : Comment 0

중재법 주요조항 정리

제3조(정의) 이 법에서 사용하는 용어의 뜻은 다음과 같다.

1. "중재"란 당사자 간의 합의로 재산권상의 분쟁 및 당사자가 화해에 의하여 해결할 수 있는 비재산권상의 분쟁을 법원의 재판에 의하지 아니하고 중재인의 판정에 의하여 해결하는 절차를 말한다.

2. "중재합의"란 계약상의 분쟁인지 여부에 관계없이 일정한 법률관계에 관하여 당사자 간에 이미 발생하였거나 앞으로 발생할 수 있는 분쟁의 전부 또는 일부를 중재에 의하여 해결하도록 하는 당사자 간의 합의를 말한다.

제8조(중재합의의 방식) ① 중재합의는 독립된 합의 또는 계약에 중재조항을 포함하는 형식으로 할 수 있다. ② 중재합의는 서면으로 하여야 한다.

③ 다음 각 호의 어느 하나에 해당하는 경우는 서면에 의한 중재합의로 본다.

1. 구두나 행위, 그 밖의 어떠한 수단에 의하여 이루어진 것인지 여부와 관계없이 중재합의의 내용이 기록된 경우

2. 전보, 전신, 팩스, 전자우편 또는 그 밖의 통신수단에 의하여 교환된 전자적 의사표시에 중재합의가 포함된 경우. 다만, 그 중재합의의 내용을 확인할 수 없는 경우는 제외한다.

3. 어느 한쪽 당사자가 당사자 간에 교환된 신청서 또는 답변서의 내용에 중재합의가 있는 것을 주장하고 상대방 당사자가 이에 대하여 다투지 아니하는 경우

④ 계약이 중재조항을 포함한 문서를 인용하고 있는 경우에는 중재합의가 있는 것으로 본다. 다만, 중재조항을 그 계약의 일부로 하고 있는 경우로 한정한다.

제9조(중재합의와 법원에의 제소) ① 중재합의의 대상인 분쟁에 관하여 소가 제기된 경우에 피고가 중재합의가 있다는 항변을 하였을 때에는 법원은 그 소를 각하하여야 한다. 다만, 중재합의가 없거나 무효이거나 효력을 상실하였거나 그 이행이 불가능한 경우에는 그러하지 아니하다. ② 피고는 제1항의 항변을 본안에 관한 최초의 변론을 할 때까지 하여야 한다. ③ 제1항의 소가 법원에 계속 중인 경우에도 중재판정부는 중재절차를 개시 또는 진행하거나 중재판정을 내릴 수 있다.

제35조(중재판정의 효력) 중재판정은 양쪽 당사자 간에 법원의 확정판결과 동일한 효력을 가진다. 다만, 제38조에 따라 승인 또는 집행이 거절되는 경우에는 그러하지 아니하다.

제36조(중재판정 취소의 소) ① 중재판정에 대한 불복은 법원에 중재판정 취소의 소를 제기하는 방법으로만 할 수 있다.

② 법원은 다음 각 호의 어느 하나에 해당하는 경우에만 중재판정을 취소할 수 있다.

1. 중재판정의 취소를 구하는 당사자가 다음 각 목의 어느 하나에 해당하는 사실을 증명하는 경우

가. 중재합의의 당사자가 해당 준거법에 따라 중재합의 당시 무능력자였던 사실 또는 중재합의가 당사자들이 지정한 법에 따라 무효이거나 그러한 지정이 없는 경우에는 대한민국의 법에 따라 무효인 사실

나. 중재판정의 취소를 구하는 당사자가 중재인의 선정 또는 중재절차에 관하여 적절한 통지를 받지 못하였거나 그 밖의 사유로 변론을 할 수 없었던 사실

다. 중재판정이 중재합의의 대상이 아닌 분쟁을 다룬 사실 또는 중재판정이 중재합의의 범위를 벗어난 사항을 다룬 사실. 다만, 중재판정이 중재합의의 대상에 관한 부분과 대상이 아닌 부분으로 분리될 수 있는 경우에는 대상이 아닌 중재판정 부분만을 취소할 수 있다.

라. 중재판정부의 구성 또는 중재절차가 이 법의 강행규정에 반하지 아니하는 당사자 간의 합의에 따르지 아니하였거나 그러한 합의가 없는 경우에는 이 법에 따르지 아니하였다는 사실

2. 법원이 직권으로 다음 각 목의 어느 하나에 해당하는 사유가 있다고 인정하는 경우

가. 중재판정의 대상이 된 분쟁이 대한민국의 법에 따라 중재로 해결될 수 없는 경우

나. 중재판정의 승인 또는 집행이 대한민국의 선량한 풍속이나 그 밖의 사회질서에 위배되는 경우

③ 중재판정 취소의 소는 중재판정의 취소를 구하는 당사자가 중재판정의 정본을 받은 날부터 또는 제34조에 따른 정정ㆍ해석 또는 추가 판정의 정본을 받은 날부터 3개월 이내에 제기하여야 한다. ④ 해당 중재판정에 관하여 대한민국의 법원에서 내려진 승인 또는 집행 결정이 확정된 후에는 중재판정 취소의 소를 제기할 수 없다.

제37조(중재판정의 승인과 집행) ① 중재판정은 제38조 또는 제39조에 따른 승인 거부사유가 없으면 승인된다. 다만, 당사자의 신청이 있는 경우에는 법원은 중재판정을 승인하는 결정을 할 수 있다. ② 중재판정에 기초한 집행은 당사자의 신청에 따라 법원에서 집행결정으로 이를 허가하여야 할 수 있다. ③ 중재판정의 승인 또는 집행을 신청하는 당사자는 중재판정의 정본이나 사본을 제출하여야 한다. 다만, 중재판정이 외국어로 작성되어 있는 경우에는 한국어 번역문을 첨부하여야 한다. ④ 제1항 단서 또는 제2항의 신청이 있는 때에는 법원은 변론기일 또는 당사자 쌍방이 참여할 수 있는 심문기일을 정하고 당사자에게 이를 통지하여야 한다. ⑤ 제1항 단서 또는 제2항에 따른 결정은 이유를 적어야 한다. 다만, 변론을 거치지 아니한 경우에는 이유의 요지만을 적을 수 있다. ⑥ 제1항 단서 또는 제2항에 따른 결정에 대해서는 즉시항고를 할 수 있다. ⑦ 제6항의 즉시항고는 집행정지의 효력을 가지지 아니한다. 다만, 항고법원(재판기록이 원심법원에 남아 있을 때에는 원심법원을 말한다)은 즉시항고에 대한 결정이 있을 때까지 담보를 제공하게 하거나 담보를 제공하게 하지 아니하고 원심재판의 집행을 정지하거나 집행절차의 전부 또는 일부를 정지하도록 명할 수 있으며, 담보를 제공하게 하고 그 집행을 계속하도록 명할 수 있다. ⑧ 제7항 단서에 따른 결정에 대해서는 불복할 수 없다.

KASAN_중재법 주요조항 정리.pdf

KASAN_특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플.p

Tags : 계약분쟁, 국제계약, 기술이전, 라이선스, 라이센스, 분쟁해결, 영문계약, 중재, 중재법, 중재합의

작성일시 : 2019.05.29 08:21
Trackback 0 : Comment 0

특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플

2. LICENSE GRANT.

2.1 License Grant to A.

Subject to the terms and conditions of this Agreement, Licensor M hereby grants to Licensee A an exclusive (even as to M and its Affiliates), royalty-bearing license, with the right to grant sublicenses through multiple tiers (subject to Section 2.2), under the M Know-How and M Patent Rights, to Develop, manufacture, use, sell, offer for sale, import, export and otherwise Commercialize Licensed Products in the Territory subject to and in accordance with the terms and conditions of this Agreement. The foregoing license includes the right to have any of the foregoing performed pursuant to Section 2.2.

2.2 Sublicense and Subcontracting Rights.

Licensee A shall require A’s Sublicensees to agree in writing to be bound by all of the applicable terms and conditions of this Agreement. A’s grant of any sublicense shall not relieve A from any of A’s obligations under this Agreement, and A shall remain jointly and severally liable for any uncured breach of a sublicense by a Sublicensee of A to the extent that such uncured breach would constitute a breach of this Agreement. A shall have the right to retain a Third Party contractor to perform any activity in connection with A’s exercise of any of its rights granted under Section 2.1, where such activity is to be performed at the direction and control and for the sole benefit of A or its Affiliates. A shall ensure that any and all activities performed by the Third Party contractor comply in all respects with the terms and conditions of this Agreement, and shall remain primarily liable for all such activities of the Third Party contractor. Such retention of the Third Party contractor is not a sublicense within the meaning of this Section 2.2 but is considered an activity of A under the license granted in Section 2.1.

2.3 Certain Restrictions.

(a) Except as otherwise expressly provided in Section 2.4, Licensor M agrees that it shall not, and will cause its Affiliates to not, offer to sell, license or otherwise provide any rights, including for example distribution rights, to Licensed Products, or under M Patent Rights or M Know How, to any Third Party if M or its relevant Affiliates, knows, or has a reason to believe (i) that such Licensed Product would be sold or transferred into the Territory; or (ii) that M Patent Rights or M Know How would be used, directly or indirectly, to manufacture, develop or commercialize a Licensed Product, or any product that would be reasonably expected to compete with a Licensed Product, or any product that would infringe at least one Valid Claim of a M Patent Right, which product, in each case, would be sold or transferred into the Territory. M agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from actions described in this Section 2.3(a).

(b) Licensee A agrees that it shall not, and will cause its Affiliates to not, (i) offer to sell or otherwise provide Licensed Products to any Third Party if A or its relevant Affiliates, knows, or has reason to believe that the Licensed Product offered for sale, sold or provided to such Third Party would be, directly or indirectly, sold or transferred into North Korea or into South Korea; and (ii) use or practice under any intellectual property right licensed to it under this Agreement except as expressly permitted by this Agreement. A agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from such actions described in Section 2.3(b)(i) and (ii).

2.4 Reservation of Rights.

(a) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to (i) Manufacture Licensed Products and supply such Licensed Products to A pursuant to the terms of the Supply Agreement, (ii) develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize the M Products anywhere in the world, (iii) subject to Section 2.5, develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize MT10 (but not any formulation thereof other than the lyophilized formulation of M’s proprietary 150kDa botulinum toxin type A product without human serum albumin) anywhere in the world either itself or through a Third Party, and (iv) develop, manufacture and use, sell, offer for sale, import, export and otherwise commercialize, under the M Know-How and M Patent Rights, any M Product that complies with cGMP (a “cGMP M Product”) anywhere in the world either by itself or through a Third Party; provided that, notwithstanding anything to the contrary, if M develops any cGMP M Product, M shall not, and shall not license, authorize or otherwise permit any Third Party to, at any time during the Term, (A) file for Regulatory Approval of a cGMP M Product in any country in the Territory as a “biosimilar” or a “follow-on biologic” or a “subsequent entry biologic” or other comparable term under applicable regulatory regimes in such country, or (B) market, promote, sell, offer for sale, import, export or otherwise commercialize a cGMP M Product anywhere in the United States or anywhere in Canada or in any Member country of the European Union.

(b) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to use, sell, offer for sale, import, export and otherwise Commercialize MT10 in Japan, but only in Japan and in no other country in the Territory; provided that (i) M and A shall be co-exclusive with respect to such activities with respect to MT10 in Japan, (ii) M may not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise, and (iii) M shall have no right to grant sublicense rights to any Third Party with respect to MT10 in Japan but shall have the right to grant sublicense rights to an Affiliate of M in Japan; provided that, with respect to any such Affiliate, (A) M has a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate and (B) no competitor of A has any control or equity interest in such Affiliate, in both (A) and (B), as of the effective date of such sublicense and remains so throughout the term of the sublicense. For purposes of clarification, in the event that M grants a sublicense to an Affiliate of M pursuant to (iii) above and, at any time after the effective date of the sublicense, either (1) M does not have a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate or (2) a competitor of A acquires any control or equity interest in such Affiliate whether by, for example, investment, acquisition or merger, M agrees that such sublicense shall terminate. In connection with such M retained right, A agrees that it shall not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise.

2.5 Right of First Refusal.

If Licensor M wishes to seek Regulatory Approval for and Commercialize MT10 with any Third Party, including without limitation by way of license, partnership, joint venture, collaboration, distribution or other similar relationship, Licensee A shall have a right of first refusal to obtain an exclusive (even as to M and its Affiliates) right and license to MT10 in the Territory. M shall present to A, prior to any discussion with any Third Party, a complete data package summarizing all available data with respect to the MT10 program and a good faith proposal of terms and conditions for A to obtain an exclusive right and license to MT10, and the Parties shall comply with the procedure set forth in this Section 2.5. The Parties shall proceed promptly to negotiate the terms of a definitive agreement, and shall use commercially reasonable efforts to do so within one hundred and twenty (120) days after initiating such negotiations. In the event that A and M have not agreed upon the material terms and conditions pursuant to which A would receive such a right and license to MT10 within such one hundred and twenty (120) day period after the initiation of discussions (the “ROFR Period”), M shall be free to discuss terms and conditions for the grant of rights and license with respect to MT10 with any Third Party; provided that the terms and conditions offered to the Third Party are not more favourable to such Third Party than those that have been offered to A. If M has not entered into a definitive written agreement with a Third Party with respect to MT10 within nine (9) months after the later of (i) the date of the expiration of the ROFR Period and (ii) the date of the termination of the negotiations between M and A regarding the terms and conditions of a license to MT10, then M shall not offer to any Third Party any rights to MT10 unless and until M has first offered A a further right of first refusal to obtain such a license, which further right of first refusal shall operate in accordance with the terms of this Section 2.5.

2.6 No Implied Rights or Licenses.

Licensor M grants no additional rights or licenses in or to any Patent or other intellectual property right, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this Agreement.

KASAN_미국회사 – 한국회사 사이 기술이전, 라이선스, 생산납품 영문계약서에 사용된 일반조항 GENERAL PR

Tags : Grant, 국제계약, 기술이전, 라이선스, 라이센스조항, 바이오의약, 영문계약, 영업비밀, 특허실시

작성일시 : 2019.05.28 13:04
Trackback 0 : Comment 0

미국회사 – 한국회사 사이 기술이전, 라이선스, 생산납품 영문계약서에 사용된 일반조항 GENERAL PROVISIONS 계약조항 샘플 – 구글에 공개된 영문계약서

19.1 Change of Control

(a) Upon a change of control of MEDYTOX, ALLERGAN, in its sole discretion, shall have the right to provide written notice to MEDYTOX that, effective as of the date of such written notice, (a) ALLERGAN shall have no obligation to provide any forward looking reports to MEDYTOX pursuant to Section 3.1(e) or otherwise under the terms of this Agreement, (b) the license granted by ALLERGAN to MEDYTOX pursuant to Section 9.2(c) shall terminate and all rights granted to MEDYTOX pursuant to such Section 9.2(c) shall revert to ALLERGAN, (c) any and all rights held by MEDYTOX with respect to ALLERGAN Data pursuant to Section 4.7 shall terminate and all rights held by MEDYTOX pursuant to Section 4.7 shall revert to ALLERGAN, and (d) any and all rights held by MEDYTOX with respect to Patents covering the use of products for Indications pursuant to Section 4.7(c) shall terminate and all rights held by MEDYTOX with respect to such Patents shall revert to ALLERGAN.

(b) For purposes of this Section 19.1, the term “change of control” shall mean the closing of (i) any consolidation or merger of MEDYTOX with or into any other corporation or entity, (ii) a sale of either substantially all of the assets of or a substantial portion of the stock in MEDYTOX, or (iii) any other transaction or series of related transactions; provided that, in each of cases (i), (ii) and (iii), as a result of such consolidation, merger, sale or other transaction(s), after such closing at least fifty percent (50%) of the voting power of MEDYTOX, or the surviving entity, or the parent of the surviving entity shall be owned by a competitor of Allergan in neurotoxin business except the stockholders of MEDYTOX immediately prior to the closing thereof. Not later than the date of any public announcement that MEDYTOX may undergo, or anticipates undergoing, a change of control, MEDYTOX shall provide written notice thereof to ALLERGAN including in such written notice the identity of the party or parties in the consolidation, merger, sale or other transaction(s) that, if completed, would constitute a change of control of MEDYTOX. In addition, after delivery of such written notice to ALLERGAN, MEDYTOX shall provide assistance to ALLERGAN, as requested and reasonably required by ALLERGAN, to permit ALLERGAN to evaluate whether to exercise its rights under this Section 19.1.

19.2 Agency

Neither Party is, nor shall be deemed to be, an employee, agent, partner or co-venturer, or legal representative of the other Party for any purpose. Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the other Party, assume any obligations for the other Party or make any representations or warranties on behalf of that other Party, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so.

19.3 Assignment.

Neither this Agreement, nor any of the rights and obligations hereunder shall be assigned or, except as expressly permitted hereby, delegated, by any Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld, delayed, or conditioned); provided, however, (i) the assignment of this Agreement by operation of law pursuant to a merger or consolidation of either Party with or into any Third Party shall, regardless of the identity of the surviving entity to such merger or consolidation, be permitted, (ii) either Party, without such consent, may assign its rights and delegate its obligations hereunder to an Affiliate thereof without obtaining such consent, and (iii) either Party, without such consent, may assign its rights and delegate its obligations hereunder to a successor entity or acquirer of such Party or of all or substantially all of such Party’s business to which this Agreement relates. In the event of an assignment of this Agreement or any of the rights and obligations hereunder pursuant to this Section 19.3, the assigning Party shall remain primarily liable for the full and timely performance by the assignee of all its obligations hereunder. This Agreement shall be binding upon and inure to the benefit of, the Parties and their respective successors and permitted assignees and the name of a Party appearing herein shall be deemed to include the names of such Party’s successor’s and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 19.3 shall be null and void.

19.4 Further Actions.

Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other acts, as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement.

19.5 Enforcement of Rights and Obligations.

Any obligation of MEDYTOX under this Agreement shall be deemed fully performed if performed with respect to any one of AP Ireland, APHI or Allergan, Inc. MEDYTOX shall be entitled to enforce its rights under this Agreement against any one of AP Ireland, APHI or Allergan, Inc., and each of the foregoing ALLERGAN parties shall remain jointly and severally liable to MEDYTOX for any and all obligations of ALLERGAN under this Agreement.

19.6 Notice.

All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice; provided that notices of a change of address shall be effective only upon receipt thereof):

19.7 Amendment

No amendment, modification, or supplement of any provisions of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.

19.8 Waiver.

No provision of this Agreement shall be waived by any act, 19.8 omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.

19.9 Counterparts.

This Agreement may be executed in two or more counterparts and by facsimile or other electronic transmission, each of which shall be deemed an original and when taken together shall constitute one and the same instrument.

19.10 Construction.

The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. Except where the context otherwise requires, wherever used the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto.

19.11 Severability.

Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under Applicable Laws, but, if any provision of this Agreement is held to be prohibited by or invalid under Applicable Laws or unenforceable by a court of competent jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement.

19.12 Governing Law; Jurisdiction.

This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New York, USA, without regard to its or any other jurisdiction’s choice of law rules that would result in the application of the laws of any jurisdiction other than the State of New York, USA. Any dispute arising out of or in connection with this Agreement that is not subject to a Party’s final decision authority pursuant to Section 3.2(c) shall be finally settled by binding arbitration under the Rules of Arbitration of the International Chamber of Commerce in effect at the time of arbitration. The arbitration shall be conducted in Singapore, before a tribunal of three arbitrators, of whom one shall be nominated by MEDYTOX, one shall be nominated by ALLERGAN, and the third one shall be selected by the foregoing two nominees. The arbitration proceedings shall be in English. All decisions of the arbitration tribunal shall be final and binding on the Parties and shall be enforceable in accordance with their terms.

19.13 Compliance with Applicable Laws.

Each Party will comply with all Applicable Laws, including, where applicable, then-current Good Laboratory Practices, and then-current Good Manufacturing Practices, and then-current Good Clinical Practices, in performing its obligations and exercising its rights hereunder, including without limitation the performance of activities connected with the Development, Manufacture, and Commercialization (as applicable) of Licensed Products under this Agreement. Nothing in this Agreement shall be deemed to permit ALLERGAN to export, re-export or otherwise transfer any Information transferred hereunder or Licensed Products manufactured therefrom without complying with Applicable Laws.

19.14 Entire Agreement.

This Agreement, and the Exhibits, schedules and other attachments hereto, together with the Supply Agreement, the Quality Agreement, and the Confidential Disclosure Agreement, constitute and contain the complete, final and exclusive understanding and agreement of the Parties, and cancel and supersede any and all prior and contemporaneous negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof, and neither Party shall be liable or bound to any other Party in any manner by any representations, warranties, covenants, or agreements except as specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any Party, other than the Parties and their respective successors and assigns, any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided herein.

KASAN_기술이전, 특허라이선스 계약에서 공정거래법, Anti-trust & Fair Competition Law

Tags : 계약실무, 국제계약, 기술이전, 라이선스, 바이오의약, 생산납품계약, 실무적대응방안, 영문계약, 위탁생산, 일반조항

작성일시 : 2019.05.27 09:57
Trackback 0 : Comment 0

기술이전, 특허라이선스 계약에서 공정거래법, Anti-trust & Fair Competition Law 관련 실무적 개요

당연 위법 사항 - per se illegal

► price fixing, ► output restraint, ► market division, ► group boycott, ► resale price maintenance

경쟁제한성과 합리성 판단 사항 - Rule of Reason 적용대상

Safeguards against the anticompetitive concerns

► horizontal restraints

► tying arrangements (package licensing)

► exclusive dealing (territory, field of use, components, alternatives, etc.)

► cross-licensing and pooling arrangements

. fair, reasonable and non-discriminatory terms and conditions

. limiting to technically essential patents, not including alternatives

. free to be licensed individually or in a package

. worldwide non-exclusive

. royalties on actual use of the patents

. free to develop and use alternatives

. grant back under non-exclusive, non-discriminatory licenses

. no joint defense

► grant-back

► acquisition (exclusive licensing) of IPR

판단요소

1. Whether the restraint is likely to have anticompetitive effects?

2. Whether, under the relevant market context, the restraint is reasonably necessary to achieve pro-competitive efficiencies that outweigh anticompetitive effects?

Qualcomm 퀄컴 특허라이선스 계약의 불공정사항 수정 명령 - 미국법원 FTC v. Qualcomm 사건 2019. 5. 21. 선고 1심 판결 내용

(1) Qualcomm must not condition the supply of modem chips on a customer’s patent license status and Qualcomm must negotiate or renegotiate license terms with customers in good faith under conditions free from the threat of lack of access to or discriminatory provision of modem chip supply or associated technical support or access to software.

(2) Qualcomm must make exhaustive SEP licenses available to modem-chip suppliers on fair, reasonable, and non-discriminatory ("FRAND") terms and to submit, as necessary, to arbitral or judicial dispute resolution to determine such terms.

(3) Qualcomm may not enter express or de facto exclusive dealing agreements for the supply of modem chips.

(4) Qualcomm may not interfere with the ability of any customer to communicate with a government agency about a potential law enforcement or regulatory matter.

KASAN_특허실시, 기술이전, 라이선스 영문계약서에서 진술보증, 면책조항 관련 실무적 포인트 몇 가지 면책조항

Tags : 공정거래법, 국제계약, 라이선스, 미국판결, 불공정거래행위, 손해배상, 실무적대응방안, 퀄컴, 특허라이선스, 표준특허

작성일시 : 2019.05.23 17:00
Trackback 0 : Comment 0

특허실시, 기술이전, 라이선스 영문계약서에서 진술보증, 면책조항 관련 실무적 포인트 몇 가지 + 면책조항 INDEMNIFICATION, INSURANCE, LIMITATION OF LIABILITY 계약조항 샘플

실무적 포인트

· 진술 및 보증 조항 Rep. & Warranty

Ø 소유권/license허여권 보증 (○)

Ø 계약대상 IP의 권리 유효성 보증 (적법 등록유지 ○, 절대적 유효성 ×)

Ø 제3자의 지재권 비침해 보증 (고의침해 ○, 기타 △)

· 면책 Indemnification

Ø 지재권 침해 claim시 면책규정은 license, 공동연구발 계약협상에서 쟁점이 많은 규정

Ø 특허를 제외한 copyright등 기타 권리에 대해서는 indemnification을 대부분 수용하는 편이나, 특허에 대해서는 면책보장의 수용이 어려운 경우가 많음.

Ø 전세계 특허의 사전조사는 현실적으로 불가능하고, 고의적으로 copy한 경우가 아니더라도 유사성이 존재하는 한 침해를 구성

Ø 고의침해 경우(punitive damage대상이 됨) - 무제한 배상 보장 가능

Ø 기타 지재권 침해 claim경우 - 지불금액 총액 한도내에서 합의가 합리적

Ø 제외: - 허여 용도 외 사용, 제공기술/제품의 임의 수정, 제공 외 기술/제품과 결합, 합성 등으로 인해 침해가 발생한 경우

계약조항 영문 샘플

23. INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY.

23.1 General Indemnification by Licensor. Licensor CyDex shall defend, indemnify and hold Licensee Hospira and its Affiliates and Sublicensees, and each of their respective directors, officers, agents and employees, harmless from and against any and all losses, judgments, damages, liabilities, settlements, penalties, fines, costs and expenses (including the reasonable costs and expenses of attorneys and other professionals) (collectively “Losses”) incurred as a result of any claim, demand, action or other proceeding (each, a “Claim”) by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use, handling, promotion, marketing, distribution, importation, sale or offering for sale of Captisol by CyDex, its Affiliates or any of their agents, or (b) CyDex’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 8, or (c) any negligent or willful misconduct by CyDex or its Affiliates or any of their respective distributors, officers, directors employees or agents, in each case to the extent that such Losses are not due to Hospira’s or any of its Affiliates’ or Sublicensees’, or any of their respective directors’, officers’, agents’ or employees’ breach of this Agreement or negligence or willful misconduct.

23.2 General Indemnification by Licensee. Licensee Hospira shall defend, indemnify and hold Licensor CyDex and its Affiliates, and each of their respective directors, officers, agents and employees, harmless from and against any and all Losses incurred as a result of any Claim by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use, handling, promotion, marketing, distribution, importation, sale or offering for sale of the Finished Product by Hospira, its Affiliates and Sublicensees, or (b) Hospira’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 8, or (c) any negligent or willful misconduct by Hospira or its Affiliates or any of their respective distributors, officers, directors employees or agents, in each case to the extent that such Losses are not due to CyDex’s or any of its Affiliates’ or any of their respective directors’, officers’, agents’ or employees’ breach of this Agreement or negligence or willful misconduct.

23.4 Procedure.

(a) The person intending to claim indemnification under Section 9 (an “Indemnified Party”) shall promptly notify the other party (the “Indemnifying Party”) of any Claim in respect of which the Indemnified Party intends to claim such indemnification, and a reasonable explanation of the basis for the Claim and the amount of alleged Losses to the extent of the facts then known by the Indemnified Party. (Notwithstanding the foregoing, no delay or deficiency on the part of the Indemnified Party in so notifying the Indemnifying Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the Indemnifying Party has suffered actual prejudice directly caused by the delay or other deficiency.) The Indemnifying Party shall assume the defense thereof; provided, however, that if the Indemnifying Party assumes the defense, the Indemnified Party shall have the right to employ counsel separate from counsel employed by the Indemnifying Party in any such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified Party shall be at the sole cost and expense of the Indemnified Party unless the Indemnifying Party consents to the retention of such counsel or unless the named parties to any action or proceeding include both the Indemnifying Party and the Indemnified Party and a representation of both the Indemnifying Party and the Indemnified Party by the same counsel would be inappropriate due to the actual or potential differing interests between them. And provided further that, if the Indemnifying Party shall fail to assume the defense of and reasonably defend such Claim, the Indemnified Party shall have the right to retain or assume control of such defense and the Indemnifying Party shall pay (as incurred and on demand) the fees and expenses of counsel retained by the Indemnified Party.

(b) The Indemnifying Party shall not be liable for the indemnification of any Claim settled (or resolved by consent to the entry of judgment) without the written consent of the Indemnifying Party (which shall not be unreasonably withheld or delayed). Also, if the Indemnifying Party shall control the defense of any such Claim, the Indemnifying Party shall have the right to settle such Claim; provided, that the Indemnifying Party shall obtain the prior written consent (which shall not be unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement of (or resolving by consent to the entry of judgment upon) such Claim unless (A) there is no finding or admission of any violation of law or any violation of the rights of any Third Party by an Indemnified Party, no requirement that the Indemnified Party admit fault or culpability, and no adverse effect on any other claims that may be made by or against the Indemnified Party and (B) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party and such settlement does not require the Indemnified Party to take (or refrain from taking) any action.

(c) Regardless of who controls the defense, the other party hereto shall reasonably cooperate in the defense as may be requested. Without limitation, the Indemnified Party, and its directors, officers, advisers, agents and employees, shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigations of any Claim.

23.5 Insurance. CyDex will procure and maintain, at its own expense, for the duration of the Agreement, and for [*] thereafter if written on a claims made or occurrence reported form, the types of insurance specified below with carriers rated [*]. Best or like rating agencies:

a. Workers’ Compensation accordance with applicable statutory requirements and shall provide a waiver of subrogation in favor of Hospira;

b. Employer’s Liability with a limit of liability in an amount of not less than $[***];

c. Commercial General Liability including premises operations, products & completed operations, blanket contractual liability, personal injury including fire legal liability for bodily injury and property damage in an amount not less than $[***];

d. Commercial Automobile Liability for owned, hired and non-owned motor vehicles with a combined single limit in an amount not less than $[*];

e. Excess Liability including product liability with a combined single limit in an amount of not less than $[*];

f. Commercial Crime or Fidelity Bond in an amount of not less than $[*] including an endorsement for Third Party liability without the requirement of a conviction.

g. Cargo Legal Liability insurance covering all risks of physical loss or damage to cargo handled by CyDex. The limit of liability shall not be less than $[*].

23.6 Limitation of Liability. EXCEPT FOR (1) PERSONAL INJURY, INCLUDING DEATH, (2) TANGIBLE PROPERTY DAMAGE, (3) EACH PARTY’S INDEMNIFICATION OBLIGATIONS, (4) DAMAGES ARISING OUT OF AN INTENTIONAL BREACH OF THE CONFIDENTIALITY OBLIGATIONS HEREIN, (5) DAMAGES ARISING OUT OF CYDEX’S BREACH OF SECTION 2.4, AND (6) DAMAGES FOR WHICH CYDEX IS RESPONSIBLE PURSUANT SECTION 3.6, 3.7 OR 6.4.

KASAN_특허실시, 기술이전 라이선스, 공동연구개발계약에서 추가 연구개발 결과물, 개량발명 관련 계약조항 샘플,

Tags : 국제계약, 기술이전, 라이선스, 면책조항, 실무적대응방안, 영문계약, 진술보증, 책임면제, 책임제한, 특허라이선스

작성일시 : 2019.05.23 10:02
Trackback 0 : Comment 0

특허실시, 기술이전 라이선스, 공동연구개발계약에서 추가 연구개발 결과물, 개량발명 관련 계약조항 샘플, 법적 쟁점 및 실무적 대응방안 몇 가지

KASAN_기술이전, 라이선스 계약에서 특허기술 사용대가 로열티 vs 기술지원 비용 로열티 구분 로열티 지급과

Tags : 개량발명, 개발결과물, 공유특허, 국제계약, 권리귀속, 기술이전, 라이선스, 실무적대응방안, 영문계약, 특허라이선스

작성일시 : 2019.05.23 09:43
Trackback 0 : Comment 0

기술이전, 라이선스 계약에서 특허기술 사용대가 로열티 vs 기술지원 비용 로열티 구분 + 로열티 지급과 원천징수 문제

기술사용료 vs 기술지원 용역비 구분

구분	사용대가 사용료
개념	특허, 상표, 저작권, 기술 등 무형의 가치
원천지기준	국내세법 : 사용 또는 지급지국 기준 (국내에서 권리의 사용 또는 대가지급 시) 조세조약(우선 적용) 대부분의 경우 : 지급지국 기준 미국, 태국 : 사용지국 기준 헝가리 : 거주지국 배타적 과세
소득성격	기존에 창출된 가치에 대한 대가
제공자 책임	결과에 대한 보증의무 없음
기타 기술용역	특허권 등이나 노하우 제공에 필연적으로 부수되는 용역대가
인적용역대가와 사용료가 혼합된 경우	인적용역 부분이 보조적이며 그 금액이 크지 않은 경우 전체를 사용료로 봄
관련 물품 수입 관세 기준	수입물품에 대한 관세의 과세가격은 우리나라로 수출, 판매되는 물품에 대하여 수입자가 실제로 지급하였거나 지급하여야 할 가격에 ‘상표권 및 이와 유사한 권리를 사용하는 대가(상표사용료 + 국제마케팅비용)’ 등을 가산ㆍ조정하여 산정한 거래가격에 의하여 결정

구분	기술지원 용역비
개념	신체에 부수되어 제공되는 노무, 기능 및 기술
원천지기준	국내세법 : 수행지국 과세 조세조약(국내세법에 우선적용) 원칙: 거주지국 과세 특례: 수행지국 과세 (다음 하나에 해당 시) 1. 고정시설 유지 2. 장기체류요건(총183일 초과 체재) 3. 수취금액요건(일정금액 초과지급) ※ 수행지국 과세요건은 조세조약별로 상이
소득성격	서비스에 대한 대가
제공자 책임	일정기간 동안 용역결과에 대해 보증의무 있음
기타 기술용역	용역제공에 따른 인적․물적비용으로 실제 소요된 비용
인적용역대가와 사용료가 혼합된 경우	인적용역 부분이 합리적으로 구분가능하고 그 인적용역 부분이 사용료의 보조적이 아니며 금액이 큼
관련 물품 수입 관세 기준	개발비지급 목적이 시제품을 전달이 아니고 계약제품의 설계 등 양산을 위한 기술정보를 도입하기 위한 경우, 성능시험을 위해 반입되는 시제품의 과세가격은 용역개발비 전액이 아니라, 시제품 제작을 위해 사용된 원자재비용 및 조립 기타 가공에 소요된 비용을 과세가격으로 결정

로열티 지급과 세금 원천징수

원천소득이란 당해 소득의 원천이 되는 소재지 등이 국내인 소득을 말하며 이를 근거로 각국이 외국법인에 대해서도 과세할 수 있습니다. 우리나라 세법은 국내 원천소득을 열거하고 있고 규정되지 않은 사항은 과세 대상이 아닙니다. 원천징수란 국내사업장이 없는 외국법인에 특허사용료를 지급하는 경우와 같이 외국법인이 국내에서 올린 소득에 대하여 세금을 낼 것을 기대하기 어려운 경우 그 소득을 지급하는 자가 미리 일정액을 떼어 우리 국세청에 납부하도록 하는 제도를 말합니다.

그런데, 같은 기간 동안 동일소득에 대하여 2개국에서 중복 과세한다면 부당하기 때문에, 대부분 이중과세를 방지하기 위한 조약을 체결하고 있습니다. 이중과세 방지는 (1) 특정소득에 대하여 당해 소득의 원천지국에서 세금을 면제하여 주고 거주지국에서만 과세하도록 하는 방법, (2) 원천지 국가에서 과세하고 그 소득에 대해 거주지 국가에서 공제해주는 방법을 활용합니다. 그 중 원천징수를 하지 않는 경우 원천지국가의 조세수입을 감소시키는 측면이 있어서 통상 두 번째 내용의 조세조약으로 해결합니다. 따라서, 특별한 경우가 아닌 한 지급하는 기술료에 대해 원천징수하는 것이 원칙입니다.

그러나, 당사국 사이 조세조약에 따라 우리나라에 과세권이 없는 경우라면 국내기업이 원천징수를 할 수 없습니다. 예를 들어 특허권자 법인이 아일랜드 소재 기업인 경우 한국 아일랜드 조세협약에 따라 우리나라에서 원천징수를 할 수 없습니다. 이와 같은 이유로 애플, 화이자 등 많은 다국적 거대기업들이 아일랜드에 설립한 법인에 다수의 특허권을 양도하고, 기술 로열티를 아일랜드 법인 귀속으로 하는 경우가 많습니다.

만약, 국내기업이 외국법인에게 특허 사용료를 지급하면서 세금을 원천 징수하여야 함에도 잘못하여 이를 하지 않는 경우에는 국내기업이 그 해당부분에 대한 원천세를 부과받을 위험이 있습니다. 따라서, 원천징수 여부를 정확하게 확인해야만 이와 같은 부담을 피할 수 있습니다.

예를 들어, 아일랜드 법인이 세금 회피 목적으로 설립된 실체가 없는 Paper Company인 경우 국세청은 그 아일랜드 법인의 실체를 부인하고 그 소득의 실질 귀속자(그 법인의 투자자 등)를 찾아 한국과 그 실질 귀속자들의 거주국간의 조세조약에 따라 과세할 수 있습니다. 즉, 소득의 실질 귀속자의 국가 세율에 따라 원천징수한 것으로 보고 그 소득에 대한 법인세를 부과할 수 있습니다. 따라서, 국내기업 입장에서는 기술거래 또는 라이선스의 실질적 당사자와 다른 형식적으로 조세회피 목적으로 설립된 paper company에 불과하다는 의문이 든다면 이를 반드시 확인해야 합니다. 상대방이 조세조약을 이유로 기술 로열티에 대한 원천징수를 거부하는 경우라면 그 단계에서 반드시 조세 전문가의 검토 및 확인을 거쳐 적절한 내용으로 계약을 체결하는 것이 바람직합니다. 일단 기술로열티를 모두 지급한 후 상당 기간이 경과하였다면 추후 부과된 세금부담을 해결하기 쉽지 않을 수 있습니다.

KASAN_미국연방대법원 2019. 5. 20. 선고 Mission Product vs Tempnology 판결 -

Tags : 국제계약, 기술이전, 라이선스, 로열티지급, 사용료지급, 세무조항, 영문계약, 용역비용, 원천징수, 특허라이선스

작성일시 : 2019.05.22 15:23
Trackback 0 : Comment 0

미국연방대법원 2019. 5. 20. 선고 Mission Product vs Tempnology 판결 - 라이선스 계약서에서 계약해지 (termination) 사유 - 파산, bankruptcy 사유 발생 시 라이선스 계약의 종료 관련 라이센시의 권리 관계

미국연방대법원 판결

- Licensor 상표등록권자 Tempnology vs Licensee 상표사용권자 Mission Product

- 의류 분야 등록상표의 사용허락 라이선스 계약 기간 중 Licensor 상표등록권자 Tempnology 도산 상황 발생 – 미국법원에 소위 Chapter 11 파산신청 접수

- 미국 파산법에 따라 채무자(debtor)는 이행해야 할 계약상 채무의 이행을 거절하는 부인권(rejection) 행사할 수 있음

- 본 상표사용하락 라이선스 계약에서는 Licensor 상표권자가 채무자로 상대방 채권자, licensee에 대해 라이선스 계약상 채무이행을 거절하는 부인권 행사함.

- 라이센서의 채무는 대상 상표사용을 허여하는 내용이므로 위 부인권 행사로 licensee의 상표사용권한이 소멸되는지 쟁점

- 라이센서의 부인권 행사 후 라이센시가 상표사용을 계속하는 경우 상표권침해에 해당하는지 여부가 쟁점

- 미국연방대법원 – 라이센시 계속 상표사용권한 인정함

미국판결 요지 – 부정, 라이센시는 대상 상표를 계속 사용할 수 있음

KASAN_특허실시, 기술이전, 라이선스 계약서에서 TERMINATION 조항 – 라이센시 파산 등 일반사유 및 양

Tags : missionproduct, 계약실무, 계약종료, 국제계약, 기술이전, 도산사유, 라이선스, 미국판결, 영문계약, 파산발생

작성일시 : 2019.05.22 08:39
Trackback 0 : Comment 0

특허실시, 기술이전, 라이선스 계약서에서 TERMINATION 조항 – 라이센시 파산 등 일반사유 및 양 당사자의 계약위반으로 인한 계약종료, 계약종료 후 처리 등 계약조항 샘플

10. TERMINATION

10.1 Expiration. Subject to this Section 10 below, this Agreement shall expire, on a Licensed Product-by-Licensed Product and country-by-country basis, on the date on which Kite, its Affiliates and sublicensees permanently cease to research, develop, sell and commercialize the Licensed Product in such country (the “Term”).

10.2 Termination for Convenience. The Licensee Kite may terminate this Agreement, in its sole discretion, upon thirty (30) days prior written notice to the Licensor Cabaret and Dr. Eshhar.

10.3 Termination for Cause. Except as otherwise provided in Section 12, each party may terminate this Agreement upon or after the breach of any material provision of this Agreement by the other party if the other party has not cured such breach within sixty (60) days (or such longer period as such party may reasonably agree if said breach is incapable of cure within such sixty (60) days) after receipt of express written notice thereof by such party.

10.4 Insolvency. This Agreement may be terminated by the Licensor Cabaret in the event of an Insolvency Event occurring in relation to the Licensee Kite, by giving a notice of termination to Kite. The termination shall take effect upon delivery of the notice of termination by Cabaret. “Insolvency Event” shall mean that, with respect to Kite, any of the following occurs: (i) Kite makes any arrangement or composition with or any assignment for the benefit of its creditors generally; (ii) a petition is presented that is not dismissed within 120 days or a court order is made or a resolution is passed for the winding up of Kite or for the making of an administration order or for the appointment of a provisional liquidator or a judicial factor or similar officer in relation to Kite; (iii) an encumbrancer takes possession of or a trustee, receiver, liquidator, provisional liquidator, administrator, manager ad interim, administrative receiver, judicial factor or similar officer is appointed, in each case for all or substantially all of Kite’s intellectual property rights and such appointment materially prejudices Cabaret’s rights under this Agreement; or (iv) Kite does, or suffers to be done in relation to it, any analogous action or proceeding in any jurisdiction anywhere in the world (including without limitation any actions or proceedings relating to bankruptcy law of any nature in the United States of America).

10.5 Effect of Expiration or Termination. Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions of Sections 5.2, 8, 10.5, 10.6, 11 and 13 shall survive the expiration or termination of this Agreement. Upon any termination of this Agreement, all licenses granted herein shall terminate, nevertheless, Cabaret shall grant a direct license to any Sublicensee of Kite hereunder having the same scope as such sublicense and on terms and conditions no less favorable to such Sublicensee than the terms and conditions of this Agreement, provided that such Sublicensee is not in default of any applicable obligations under this Agreement and agrees in writing to be bound by the terms and conditions of such direct license.

10.6 Termination Fee. In the event that Kite terminates this Agreement termination for convenience under Section 10.2 prior to the third (3rd) anniversary of the Effective Date, Kite shall pay to Cabaret a termination fee in an amount equal to US$500,000 within thirty (30) days of such termination.

KASAN_라이선스 계약서에서 계약해지 (termination) 사유 - 부도, 압류 등 파산, bankruptcy

Tags : Term, Termination, 계약기간, 계약서샘플, 계약위반, 계약종료, 국제계약, 라이선스, 영문계약, 해지

작성일시 : 2019.05.21 14:48
Trackback 0 : Comment 0

라이선스 계약서에서 계약해지 (termination) 사유 - 부도, 압류 등 파산, bankruptcy 관련 사유 발생 시 라이선스 계약의 법률관계 – 미국연방대법원 2019. 5. 20. 선고 Mission Product vs Tempnology 판결

계약실무 관행 및 실무적 쟁점

- 실무상 통상적으로 계약해지 Termination 사유로 당사자 부도, 압류, 파산 등을 규정함

- 그러나 국가마다 차이가 있지만 실제 파산 발생 시 termination 조항의 상대방의 계약 해제권 조항은 무효가 되어 아무런 의미가 없는 경우가 많다는 점을 유의해야 함

- 강행법규인 파산법에 따른 파산재산관리/분배규정에 따라, 계약이행상 상당한 변경이 발생할 수 있음

- 미국연방파산법에서는 원칙적으로 미이행계약에 대해서는 파산신청 즉시 automatic stay (자동정지) 발효

- 채무자의 계약상대방은 계약상 허여된 모든 권리 행사는 물론, (금전적 손해배상 청구 외에는) 채무자를 상대로 한 어떤 claim이나 소송도 금지

- 파산관재인은 스스로의 business judgment에 따라, 해당 계약을 거부할 수 있음은 물론(채무자는 계약이행의무가 면제됨), ‘Ipso facto’ 규정 [bankruptcy 발생 시 상대방의 계약 해제권 또는 특정 option 행사권(escrow상 금액/자료 등 인출권한) 발동조항 등]은 무효가 됨

- Licensor의 bankruptcy 경우에는 해당 license계약상 명시적인 non- assignment 규정이 있는 경우에도, 관재인은 해당 license 계약을 제3자에게 양도할 수 있는 반면,

- 프랑스, 독일에서는 파산관재인은 라이센스 계약을 미이행 계약으로서 해제할 수 있고, 이것에 대해서 특별한 Licensee 보호 제도는 마련되어 있지 않다.

- 파산관재인이 라이선스 계약의 거절을 선택했을 경우에는 licensee는 라이선스의 유지를 선택할 수 있고, 이 경우 기존 라이센스의 범위 내(단, licensor의 특정이행 의무 등의 부수적인 의무는 제외)에서 보호된다.

계약실무상 대응방안

- 파산신청 전에 예견될 수 있는 일정 기준 이하의 재정부실, 이행 지연 등을 계약 해지사유로 규정

- 파산신청 전에 발생할 수 있는 Change of control 관련 사안을 해지사유로 규정 라이선스 계약을 미이행계약으로 해석되지 않는 구조로 설정

- 예: 로열티 지불의무 외에는 실질적인 미이행 의무가 존재치 않도록 규정하고, 다른 의무 (특허 유지/관리의무 등) 는 별도의 미이행계약으로 구성

- Source Code를 제3자 보관 또는 Escrow 위탁 의무가 발생하는 경우를 설정하고, 그 경우 보관/위탁된 source code가 관재인의 control 또는 파산재산 범위에 속하지 않도록 규정 해당 특허권에 대한 담보권 설정

미국판결 사안의 쟁점 및 판단 요지

- The question is whether the debtor-licensor’s rejection of that contract deprives the licensee of its rights to use the trademark. We hold it does not.

- 쟁점: 라이센서, 등록권자가 계약서 termination 조항의 사유 – 파산을 이유로 라이선스 계약을 종료하고 라이센시의 상표사용을 금지할 수 있는지 여부

- 미국대법원 판단요지 – 부정, 라이센시는 대상 상표를 계속 사용할 수 있음 \

- A rejection breaches a contract but does not rescind it. And that means all the rights that would ordinarily survive a contract breach, including those conveyed here, remain in place.

- 상표사용 허락 라이선스 거절은 계약위반에 해당함

첨부: 미국연방대법원 판결

미국연방대법원 2019. 5. 20. 선고_Mission Product _vs_Tempnology_17-1657_판

KASAN_기술이전, 특허 라이선스 계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTI

Tags : missionproduct, 계약실무, 계약종료, 국제계약, 기술이전, 도산사유, 라이선스, 미국판결, 영문계약, 파산발생

작성일시 : 2019.05.21 11:40
Trackback 0 : Comment 0

기술이전, 특허 라이선스 계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTIES 계약조항 샘플

10. REPRESENTATIONS, WARRANTIES, AND COVENANTS.

10.1 Mutual Representations and Warranties. Licensor and Licensee (each, a “Representing Party”) each hereby represents and warrants to each other, as of the Effective Date and except as otherwise set forth in Schedule 10.2 (in the case of Licensor) and Schedule 10.3 (the case of Licensee), that:

(a) such Representing Party is a corporation or limited liability company, as applicable, duly organized and subsisting under the laws of its jurisdiction of organization;

(b) such Representing Party has the power, authority, and legal right, and is free, to enter into this Agreement on behalf of itself and its Affiliates and to perform its respective obligations hereunder and to cause its Affiliates to perform their respective obligations hereunder;

(c) such Representing Party has the power, authority, and legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement;

(d) this Agreement constitutes a legal, valid, and binding obligation of such Representing Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity;

(e) the execution and delivery of this Agreement and the performance of such Representing Party’s and its Affiliates’ obligations hereunder (i) have been duly authorized and approved by all necessary action by such Representing Party, and all necessary consents, approvals, and authorizations of all Regulatory Authorities and other Third Parties required to be obtained by such Representing Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained; (ii) do not conflict with or violate any requirement of Applicable Laws or any provision of the articles of incorporation, bylaws, limited partnership agreement, or any similar instrument of such Representing Party, as applicable, in any material way; and (iii) do not, and will not, conflict with or otherwise interfere with in such a manner as to result in a violation, breach, or default under or require any consent that has not been obtained under any contract between such Representing Party and any Third Party;

(f) there are no, and shall be no, liens, conveyances, mortgages, assignments, encumbrances, or other agreements that would prevent or impair such Representing Party’s or any of its Affiliates’ full and complete exercise of the terms and conditions of the Agreement;

(g) such Representing Party and its Affiliates shall at all times comply with all Applicable Laws relating or pertaining to their obligations under the Agreement;

(h) with respect to the services provided hereunder to the other Party, its Affiliates, and their respective employees, officers, contractors and agents who perform such services have the experience, capability, and resources to efficiently and skillfully perform the services, and shall perform, where applicable, all such services in a professional and workmanlike manner and in accordance with the generally accepted then-current standards, forms, procedures, and techniques established from time to time by the industry;

(i) all of such Representing Party’s employees, officers, contractors, and consultants have executed agreements requiring assignment to such Representing Party of all inventions created by such persons in the course of their employment by such Representing Party and obligating each such employee, officer, contractor, and consultant to maintain and safeguard the confidentiality of (i) any information that is confidential to such Representing Party or (ii) any information that is confidential to any other Person and that such Representing Party is obligated to maintain and safeguard as confidential; and

(j) neither such Representing Party, nor any of its employees, officers, subcontractors, or consultants who have rendered or will render services relating to the Product: (i) has ever been debarred or is subject or debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a or (ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a.

10.2 Additional Representations, Warranties, and Covenants of Licensor. Licensor hereby represents, warrants, and covenants to Licensee, as of the Effective Date and except as otherwise set forth in Schedule 10.2, that:

(a) Licensor is entitled to grant the rights and licenses purported to be granted to Licensee under this Agreement, and to assign the rights purported to be assigned to Licensee under this Agreement, and is not currently bound by any agreement with any Third Party, or by any outstanding order, judgment, or decree of any court or administrative agency, that restricts it from granting to Licensee the rights, licenses and sublicenses purported to be so granted in this Agreement;

(b) Licensor is the sole and exclusive owner of all right, title, and interest, in, to, and under the Licensed Rights and has the right under the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights to grant the sublicenses thereunder in accordance with Section 2.2;

(c) the Licensed Rights are free and clear of any liens, charges, encumbrances, or judgments, and Licensor has sufficient rights to grant the licenses and rights purported to be granted herein, free and clear of any security interests, claims, encumbrances, or charges of any kind;

(d) Licensor has not granted, and will not grant during the term of this Agreement, any right, option, license, or interest in or to any of the Licensed Rights that is in conflict with the rights assigned or granted to Licensee under this Agreement;

(e) there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any nature, judgment, decree, decision, injunction, writ, or order pending, or to Licensor’s knowledge threatened by, against or involving Licensor, regarding the Licensed Rights, whether at law or in equity, before or by any Third Party, and Licensor has not received any written communications alleging that it has violated, through the manufacture, Development, import, or other exploitation of the Product, any intellectual property rights of any Third Party;

(f) to Licensor’s knowledge:

(i) the patents in the issued Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent Rights are valid and enforceable; and

(ii) no Third Party has asserted that any of the Licensed Rights or the Sublicensed Rights is invalid or unenforceable;

(g) all applications, registrations, maintenance and renewal fees due in respect of any of the Licensed Serenity Patent Rights and, to Licensor’s knowledge, the Licensed Reprise Patent Rights and the Licensed CPEX Patent Rights, have been paid and all documents and certificates required to be filed with the relevant agencies for the purpose of maintaining such Licensed Serenity Patent Rights, and to Licensor’s knowledge, the Licensed Reprise Patent Rights and Licensed CPEX Patent Rights have been filed;

(h) none of the Licensed Serenity Patent Rights, the Licensed Serenity Know-How and, to Licensor’s knowledge, none of the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights were developed with funding from any Governmental Authority such that any Governmental Authority has any march in rights or other rights to use the Licensed Serenity Patent Rights, the License Serenity Know-How, the Licensed Reprise Patent Rights, or the Licensed CPEX Patent Rights;

(i) to Licensor’s knowledge, no Third Party has infringed or misappropriated any of the Licensed Rights or the Sublicensed Rights;

(j) all inventors of any inventions included within the Licensed Serenity Patent Rights and, to the knowledge of Licensor, the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights have assigned their entire right, title, and interest in and to such inventions and the corresponding patents and patent applications to Licensor, Reprise, or CPEX, as applicable, and have been listed as inventors in the Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent Rights, as applicable;

(k) no agreements that Licensor or its Affiliates may have with any Third Party provide such Third Party with any rights of first offer, rights of first refusal, or any other rights to make, have made, use, conduct Clinical Studies for, sell, offer for sale, have sold, import, export, or otherwise Exploit the Product in the Field in the Territory or the right to use the Licensed Rights or the Sublicensed Rights in connection with the Exploitation of the Product in the Field in the Territory; and Licensor has received no notice from a Third Party of any suit, action, proceeding, or arbitration pending or threatened against it that the proposed terms and conditions of this Agreement, and the Parties’ performance in accordance therewith, do or shall conflict or interfere with in a manner resulting in a breach or default under, or other violation of, any agreements that Licensor or its Affiliates may have with any Third Party;

to Licensor’s knowledge, (i) each of the CPEX License Agreement and the Reprise License Agreement is valid and enforceable in accordance with its terms, is in full force and effect, and there are no approvals or consents required to make it effective, (ii) Licensor has supplied Licensee with a true and correct copy of the CPEX License Agreement and the Reprise License Agreement , together with all amendments, waivers, or other changes thereto, (iii) Licensor has performed all material obligations required to be performed by it in connection with the CPEX License Agreement and the Reprise License Agreement, (iv) Licensor shall not materially breach and is not in material breach of the CPEX License Agreement or the Reprise License Agreement, (v) Licensor is not in receipt of any claim of default, cure notice, or show cause notice under the CPEX License Agreement or the Reprise License Agreement, and (vi) there is no current material breach or anticipated material breach by any other party to the CPEX License Agreement or the Reprise License Agreement;

(m)

(i) Licensor is the named sponsor of the First Approved NDA for the Product; and (ii) with respect to all Regulatory Documentation to obtain Regulatory Approvals for the Product in the Field: (A) the data, information and/or all other documents in Licensor’s or its Affiliates submissions were, are and shall be free from fraud or material falsity, and neither Licensor nor its Affiliates has made any material misrepresentation or omission in connection with such data; (B) the Regulatory Approvals have not been and will not be obtained either through bribery or the payment of illegal gratuities by Licensor; (C) the data, information and/or all other documents in Licensor’s or its Affiliates’ submissions are, were and shall be accurate and reliable for purposes of supporting approval of the submissions; and (D) the Regulatory Approvals shall be obtained without illegal or unethical behavior of any kind by Licensor or its Affiliates; provided that Licensor shall not be deemed to be in breach of this Section 10.2(m) if the violation of this Section 10.2(m) results from the action or omission of Licensee of Licensee’s Affiliates, Sublicensees, or contractors (other than Licensor);

(n) Licensor believes in good faith, based on the information set forth in Schedule 10.2(n), that FDA will consider amending or supplementing the First Approved NDA (or the related IND) in the manner described in Schedule 10.2(n); provided, however, that Licensor cannot assure that FDA will approve such amendment or supplement.

(o) except as expressly permitted hereunder, Licensor agrees not to, and agrees to cause its Affiliates and Sublicensees not to (i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, or (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse or other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product; and

(p) other than the CPEX License Agreement, the Reprise License Agreement, the Renaissance Supply Agreements, and the other Third Party Supply Agreements, Licensor and/or its Affiliates have not entered into any agreements with any Third Party, pursuant to which any Third Party has granted to Licensor, or Licensor has granted to any Third Party, any rights to licenses to, in or under any of the Licensed Rights or the Sublicensed Rights or other intellectual property rights that relate to the Product, or relating to the manufacture of the Product.

10.3 Additional Representations, Warranties, and Covenants of Licensee. Licensee hereby represents, warrants, and covenants to Licensor, as of the Effective Date and except as otherwise stated in Schedule 10.3, that:

(a) if, during the term of this Agreement Licensee has reason to believe that it or any of its employees, officers, subcontractors, or consultants rendering services relating to the Product: (i) is or will be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or will be under indictment under said Section 335a, then Licensee shall immediately notify Licensor in writing;

(b) as of the Effective Date, there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any nature, judgment, decree, decision, injunction, writ, or order pending or, to the knowledge of Licensee’s senior management, threatened by, against Licensee regarding this Agreement, whether at law or in equity, before or by any Third Party; and Licensee shall provide notice of any of the foregoing to the extent it affects Licensee’s performance of its obligations under this Agreement;

(c) except for information provided by Licensor, its Affiliates or Sublicensees: (i) the data and information in Licensee’s submissions and modifications of Regulatory Documentation relating to the Product shall be free from fraud or material falsity; (ii) Regulatory Approvals for the Product hereafter obtained will not be obtained either through bribery or the payment of illegal gratuities by Licensee; (iii) the data and information in Licensee’s submissions and modifications of any Regulatory Documentation shall be accurate and reliable; and (iv) any such the Regulatory Approvals will be obtained without illegal or unethical behavior of any kind by Licensee; provided that Licensee shall not be deemed to be in breach of this Section 10.3(c) if the violation of this Section 10.3(c) results from the action or omission of Licensor or its Affiliates, Sublicensees (other than Licensee), or contractors; and

(d) except as expressly permitted hereunder, Licensee agrees not to, and agrees to cause its Affiliates and Sublicensees not to (i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse or other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, or (iv) bring any action or proceeding or otherwise assert any claim under any Applicable Law in the event any licensee (or sublicensee or any entity or person acting on its behalf) initiates any proceeding or otherwise assert any claim in any court, administrative agency, or other forum with jurisdiction over such proceeding or claim, that any of the Licensed Rights or Sublicensed Rights are invalid, unenforceable, or not infringed, violated, or misappropriated. In the event that Licensee or any Affiliate or Sublicensee of Licensee initiates any proceeding or otherwise asserts any claim in violation of clause (iv) of this Section 10.3, and the result thereof is a final decision, ruling, holding, award, or other disposition to the effect that any of the Licensed Rights or Sublicensed Rights are valid, enforceable, or infringed, violated, or misappropriated, then each of the royalty rates set forth in the table in Section 8.3(a) will each be increased by [***] and the party initiating such proceeding or otherwise asserting such claim shall pay the attorneys’ fees and expenses incurred by Licensor in defending against such proceeding or claim.

10.4 Inaccuracies. Without limiting either Party’s rights and remedies at law, in equity or under this Agreement, if, at any point in time (not just at the times when the warranties are deemed granted), either Party becomes aware of any inaccuracies in the foregoing warranties and representations, such Party shall promptly notify the other Party of such inaccuracies, with a detailed written explanation.